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Abstract 
 
The prevalence of cardiovascular disease and myocardial infarction-induced heart failure has 
risen significantly over recent years, emphasising the need for new, effective therapeutic 
strategies. A promising alternative approach is the cardiac delivery of potentially 
cardioprotective and regenerative growth factors from biomaterial scaffolds. 
 
One hydrogel system that has promise in this area is an injectable enzymatically degradable 
polyethylene glycol (PEG) hydrogel. Two modifications aimed at further optimising this 
system as a regenerative medicine scaffold were explored. Firstly, the covalent addition of 
heparin into the PEG backbone was assessed for its ability to stimulate angiogenesis by 
assessing the controlled release of basic fibroblast growth factor (bFGF), vascular endothelial 
growth factor (VEGF) and placental growth factor 2 (PlGF-2), and also assaying endothelial 
cell sprouting in an in vitro 3D spheroid angiogenesis assay. The second modification involved 
overlaying an increasingly hydrolytic degradability on top of the enzymatically degradable 
background of the hydrogel. The potential of this modification to regulate the rate of hydrogel 
replacement by invading tissue was assessed in the 3D spheroid assay and a subcutaneous 
implant study in a rat model. 
 
The covalent coupling of heparin was found to substantially increase the rate of release of 
bFGF, VEGF and PlGF-2 over 20 days by 23%, 42% and 19%, respectively, relative to non-
heparinised PEG hydrogels (p<0.01). A 3D spheroid-based angiogenesis assay was modified 
for use in quantifying endothelial cell sprouting in PEG hydrogels. bFGF and VEGF were shown 
to elicit a significant increase (2.3 – 2.4-fold increase) in average cumulative sprout lengths 
relative to that seen in the control spheroids (p<0.01). However, PlGF-2 did not stimulate a 
significant response (1.4-fold increase, p=NS). In follow up studies with heparinised hydrogels, 
it was found that the 3D angiogenesis was not rigorously established and ways forward are 
discussed. 
 
Enzymatically degradable PEG hydrogels that retained their enzymatic degradability with 
increasing levels of potential for hydrolysis were formed by increasing the proportion of PEG-
acrylate (PEG-Ac) and correspondingly decreasing the portion of PEG-vinyl sulfone (PEG-VS) 
monomers. PEG-Ac forms hydrolytically unstable bonds with the peptide crosslinker whilst 
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PEG-VS forms stable linkages. This approach was shown through swelling studies to be 
capable of generating a range of hydrolytic degradation rates. Sprouting of endothelial cells 
from PEG hydrogel embedded spheroids was shown to increase as the PEG-AC concentration 
increased. Importantly, the rate of tissue invasion in vivo was also shown to be positively 
correlated with the PEG-Ac concentration. 
 
The increased utility of these hydrogels to act as delivery vehicles for therapeutic agents, 
through covalent coupling of heparin, is promising for their use as regenerative medicine 
scaffolds. Additionally, so is the ability to finely tune tissue invasion by manipulating their 
hydrolytic degradability. 
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1. Introduction 
 
1.1. Treating Myocardial Infarction-induced Heart Failure: The Need for Therapeutic 
Angiogenesis 
 
Cardiovascular disease (CVD) is one of the main causes of death in developed countries, with 
myocardial infarction (MI) being one of the leading contributors [1]. This trend is not 
dissimilar in less developed areas, like South Africa, where it was reported in 2000 that CVD 
was the second largest cause of death after HIV/AIDS [2]. This is still the case, as CVD was 
responsible for 1 million deaths in 2013 in Sub-Saharan Africa alone [3]. With the rapid rate 
of urbanisation came changes in lifestyle and, thus, a major increase in CVD [4]. These lifestyle 
changes include dietary alterations and changes in physical activity. There has been a shift 
from diets containing cereals, vegetables and fruits, to those containing processed foods high 
in fat. In addition, due to the development that has taken place in these countries, individuals 
are also now engaging in less exercise [5]. 
 
Currently, health care practitioners are seeing an increasing proportion of patients survive 
their MIs, which can be accredited to improved management of acute arrhythmias and the 
implementation of reperfusion [1]. However, with this increased survival rate, comes a 
greater prevalence of MI-induced heart failure (HF), which current therapeutic strategies are 
not proving sufficiently efficacious to overcome [1]. 
 
1.1.1. Progression to infarction 
 
Lifestyle, as well as genetic factors, play a major role in the development of CVD [6–8]. High 
plasma cholesterol levels cause lipids to accrue within coronary arteries and these levels alter 
the permeability of the endothelial cells lining the vessel walls, allowing lipids into the vessel 
wall itself. Immune cells are also able to penetrate the vessel wall by binding to proteins now 
expressed by the altered endothelial cells which then initiates the inflammatory process of 
atherosclerosis [9]. 
 
It is mainly through the rupture of this atherosclerotic plaque, and the thrombus formation 
that follows, that a coronary artery is occluded and an MI takes place [10,11]. This occlusion 
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of blood to the heart causes the region that the blocked vessel supplies to become ischemic 
[12]. This absence of oxygen and nutrients causes extensive cardiomyocyte death, producing 
an acellular, non-contractile area known as the “infarct” [13,14]. Due to the heart’s very 
limited capacity for regeneration, this loss of cardiomyocytes at the infarct site is permanent 
[15]. 
 
The infarcted heart can then enter a vicious cycle of pathological remodelling driven, at least 
in part, by the increased workload on the surviving cardiomyocytes and the elevated stress in 
the ventricular wall due to thinning [16,17] as a consequence of cardiomyocyte loss. This 
elevated stress can be simplistically viewed as a consequence of Laplace’s Law (first applied 
to the heart by Woods in 1892 [18]): “ventricular wall stress is directly proportional to the 
diameter of the ventricle and the ventricular pressure and is inversely proportional to the wall 
thickness of the ventricle” [16]. Eventually, this ventricular stress-driven process of adverse 
remodelling leads to HF [16] where the heart is unable to meet the metabolic needs of the 
body [19]. 
 
1.1.2. Current treatment strategies 
 
Reperfusion of the blocked blood vessel by means of coronary angioplasty and/or the use of 
a stent are common strategies and can substantially limit infarct size and ventricular 
remodelling, positively influencing patient survival [20]. However, necrosis of the affected 
myocardium usually ensues quickly after the occlusion of the blood vessel. Thus, this necrosis 
often occurs before reperfusion takes place [21]. If the adverse remodelling is not prevented, 
eventually ventricular contractile function and cardiac output declines, which can progress to 
congestive HF [12]. Current treatments for MI and congestive HF include surgical procedures 
– like ventricular resection, balloon angioplasty, coronary artery bypass or the implantation 
of left ventricular assist devices – and pharmacological treatments, with diuretics and 
vasodilators being some of the strategies employed clinically, often in combination 
[12,22,23]. This approach lessens the symptoms but does not repair the damaged tissue [24]. 
Some patients are also not eligible or are entirely unresponsive to these current treatments 
[25]. Others continue to suffer symptoms of ischemic disease despite being given intense 
pharmacological treatments. Many of these individuals are not eligible for the invasive means 
of reperfusing the ischemic tissue by angioplasty or surgery [25].  
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Importantly, all of the above have proved inadequate in terms of long-term treatment [15]. 
For example, the use of diuretics may be a helpful pharmacological strategy in the short-term 
to relieve fluid accumulation, but will eventually trigger the Renin Angiotensin Aldosterone 
System due to the diuresis, vasoconstriction of renal blood vessels, and the accompanying 
decline in glomerular filtration rate [26,27]. This results in renal dysfunction and is indicative 
of a poor prognosis, with these patients needing dialysis and often being admitted to 
intensive care [28]. Although one of the main treatment goals is to achieve fluid balance in 
patients with chronic HF, hence the use of diuretics which prevent fluid reabsorption in the 
kidneys, a study (Acute Decompensated HEart Failure REgistry, or the ADHERE study) has 
found a higher mortality rate to be associated with the increased use of these diuretics 
[26,28]. 
 
The most effective “cure” for MI-induced HF is a heart transplant, however there is a great 
shortage of donors available at any given time [15]. If a patient does become a transplant 
recipient, they will need life-long immuno-suppression after surgery and further 
complications, like cardiac allograft vasculopathy, may ensue [29,30]. Thus, a need for more 
effective, alternative therapeutic strategies to treat the pathologies seen post-infarction is 
evident. 
 
1.1.3. Therapeutic angiogenesis 
 
One potential treatment approach that has emerged is therapeutic angiogenesis. 
Angiogenesis is defined as “the process of the formation of new blood vessels from pre-
existing vessels” [31]. The goal of therapeutic angiogenesis is to bring about this angiogenic 
response in a patient as a form of therapy. This allows for the re-vascularisation of ischemic 
tissue with an increased blood vessel density potentially improving tissue function [32,33]. In 
part, the therapeutic outcome is believed to derive from ameliorating the microvasculature 
damage that occurs [34], increasing capillary supply to the surviving hypertrophic 
cardiomyocytes [35] and perfusing the cardiomyocytes surrounding the infarct zone [36]. 
Therapeutic angiogenesis is often achieved through the controlled release of growth factors, 
although stimulating the expression of certain angiogenic genes and delivering stem cells 
have also been utilised [37,38]. However, the genetic and stem cell approaches do not fall 
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within the scope of this review. 
 
The Isner group are considered the pioneers of therapeutic angiogenesis. In Isner’s seminal 
work, published in 1994, it was shown that by administering a single factor, vascular 
endothelial growth factor (VEGF), in a rabbit model of hindlimb ischemia, functional 
vasculature could be created [39]. Since the publication of this work, it has become apparent 
that delivery of growth factors without a delivery vehicle, referred to as bolus delivery, has 
adverse effects and does not allow for a sufficient therapeutic duration [40,41]. Studies into 
potential delivery vehicles ensued, and the field of therapeutic angiogenesis has since 
advanced, showing promise in treating not only MI, but other pathologies, including 
cardiovascular diseases [42] like coronary artery disease, peripheral artery disease and aortic 
atherosclerosis [32]. 
 
Patients with coronary artery disease and peripheral artery disease would also benefit greatly 
from a strategy like therapeutic angiogenesis. This is because some individuals with end-stage 
coronary artery disease suffer from chronic ischaemia and do not qualify for mechanical 
means of revascularisation [43]. Similarly, some patients with critical limb ischemia, the most 
severe type of peripheral arterial disease, do not qualify for revascularization by angioplasty 
or bypass. Patients with critical limb ischemia are faced with amputation or death if not 
urgently treated [44]. Thus, in the context of these ischemic diseases, the ischemic tissue 
provides an appropriate substrate for angiogenic therapy as the lack of oxygen causes the 
expression of receptors for pro-angiogenic factors as the tissue is primed to respond to the 
therapeutic angiogenesis therapies [45,46]. If one can stimulate angiogenesis, the ischemic 
area can become reperfused, circumventing the need for surgery and providing a patient 
ineligible for invasion-based reperfusion with a non-invasive alternative [32,44]. 
 
It follows that the process of angiogenesis and the molecules involved need to be understood 
in order to bring about therapeutic angiogenesis to treat ischemic cardiovascular disease. 
 
1.1.4. The process of angiogenesis 
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Angiogenesis is involved in key physiological processes like embryonic development, 
inflammation and wound repair, but also in pathological situations like tumour growth 
[31,47]. It is a complex process involving multiple factors, thus presented below is a summary. 
 
The main trigger for physiological or pathological angiogenesis in adults is ischemia, a lack of 
sufficient oxygen and nutrient supply to the tissues [48]. This stimulates the production of 
reactive oxygen species (ROS) by vascular cells, including endothelial cells (ECs), smooth 
muscle cells (SMCs), fibroblasts and perivascular adipocytes [49]. ROS are generated by these 
cells during electron transport within the mitochondria, where oxygen is reduced through 
electron additions to form a superoxide anion, hydrogen peroxide, a hydroxyl radical, and a 
water molecule [50]. ROS can also be generated by the actions of the enzyme NADPH 
(nicotinamide adenine dinucleotide phosphate) oxidase, which transfers electrons from 
NADPH to oxygen, creating a superoxide anion [51,52]. Angiogenesis is promoted by ROS 
directly, where hydrogen peroxide induces the expression hypoxia inducible factor 1- (HIF-
1) which then stimulates the expression of VEGF in SMCs and ECs [48]. The HIF pathway is 
regarded to be the master regulator of angiogenesis [53]. Angiogenesis can also be indirectly 
stimulated by ROS through the creation of active oxidation products like peroxidised lipids, 
which is a VEGF-independent pathway [48,54]. 
 
The first step in the angiogenic process involves vasodilation stimulated by nitric oxide. In 
order for this dilation to occur, the junctions between the cells, as well as the contacts with 
perivascular cells, need to be loosened [47]. Angiopoietin-2 (Ang-2) plays a role here – by 
preventing Angiopoietin-1 (Ang-1) signalling, which promotes vessel stability, Ang-2 is able to 
destabilise the vessel and assist the detachment of pericytes and smooth muscle cells [55]. 
This also allows for ECs to migrate during the angiogenic process as this enables plasma 
proteins to extravasate and create a temporary extracellular matrix (ECM) for the ECs to move 
through [47]. The loosening of these cellular contacts is carried out by proteinases, including 
plasminogen activators and matrix metalloproteinases (MMPs), as well as other enzymes like 
chymases and heparinases [56]. Pro-angiogenic factors, like basic fibroblast growth factor 
(bFGF) and VEGF, stimulate the secretion of these proteases and plasminogen activators by 
ECs [57]. By degrading molecules in the ECM, further growth factors sequestered within are 
liberated and activated [56]. 
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These liberated factors are involved in the activation of quiescent ECs, after which they then 
adopt one of two distinct endothelial phenotypes – that of the tip cell or the stalk cell. Tip 
cells are characterized by their location, their filopodia, and their migratory behaviour. These 
cells integrate directional cues, both attractive and repulsive, from their surrounding 
environment in order to set the path for sprout growth [58]. Tip cells are also involved in 
making new connections between sprouts in order to create a connected and functional 
vasculature [59]. The cells following on from the tip cell, the stalk cells, do not produce as 
many filopodia and respond differently to VEGF by proliferating. They are responsible for 
creating tight and adherens junctions to stabilise the sprout, a lumen and “luminal/abluminal 
polarity”. This polarity is important as it leads to the deposition of a basal lamina and allows 
for recruitment and attachment of pericytes and vascular SMCs. These cells are instrumental 
in preventing vessel regression, allowing for the stabilisation and maturation of vessels 
[60,61]. In order for stalk cells to carry out these different functions, they respond to 
environmental queues differently and have different gene expression profiles compared to 
tip cells [58,62–64]. After extensive in vitro and in vivo assays, it has been found that VEGF 
and Notch signalling pathways are instrumental in the development of ECs into tip or stalk 
cells [64–66]. 
 
The Notch pathway is evolutionarily conserved and is needed for embryonic development, 
regulating tissue homeostasis, and maintaining stem cells in adults [67,68]. First identified 
in Drosophila, this pathway has since been shown to play a role in cell fate, tissue patterning, 
and morphogenesis by way of its role in cellular differentiation, proliferation, and a cell’s 
ability to survive and apoptose [69,70]. There are four Notch receptors expressed by 
mammals, with Notch 1 and Notch 4 being expressed by ECs. Ligands known as Delta, Serrate, 
LAG-2 (DSL) ligands bind to Notch receptors. Of these DSL ligands, Delta-like 1 (Dll1), Dll4, 
Jagged-1 (Jag1), and Jag2 are expressed by ECs [71–74]. 
 
VEGF binds to its tyrosine kinase receptor, VEGF receptor 2 (VEGFR2), also referred to as KDR 
in humans and Flk-1 in mice [75]. Once this takes place, the cell-surface glycoprotein 
Neuropilin 1 (Nrp1), which is considered a non-tyrosine co-receptor, acts to improve VEGF 
binding and signalling [76,77]. After VEGF has bound to its receptor and the binding and 
signalling has been treated, the quiescent ECs are activated. This binding of VEGF then causes 
an increase in Dll4 expression in the tip cells – these would be the cells closest to the source 
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of the VEGF. Dll4 then stimulates Notch signalling in the stalk cells preventing the cells from 
becoming tip cells. Notch signalling also decreases VEGFR2 expression, making these cells less 
responsive to VEGF and thus reinforcing their stalk phenotype. Instead, these cells express 
VEGF receptor 1 (VEGFR1), also known as Flt-1 in mice and FLT-1 in humans, and begin to 
express Notch target genes. Contrary to this, tip cells experience low Notch signalling [78,79]. 
This allows them to continue to have their high levels of VEGFR2 and Nrp1 expression [78]. 
Furthermore, Jag1, produced by the stalk cells, prevents Dll4-Notch signalling in the tip cells 
when under the influence of a glycosyltransferase called Fringe [73,80]. This further 
differentiates the tip/stalk phenotypes and allows for spacing between tip cells by ensuring 
not every cell stimulated by VEGF becomes a tip cell [78]. 
 
During pathological angiogenesis, placental growth factor (PlGF) is upregulated and also plays 
a role by enhancing the response to VEGF. This occurs when PlGF shifts VEGF from its 
receptor, VEGFR1, making more available to bind to VEGFR2. The enhanced angiogenic 
response is the result of the activation of both VEGFR1 and VEGFR2 [81]. It is postulated that 
PlGF may stimulate angiogenesis through the transmission of intracellular signals mediated 
by VEGFR1 [82–84]. However, it is known that VEGFR1 has a weak tyrosine kinase activity and 
its intracellular signalling requires further study. PlGF may also influence angiogenesis 
through the formation of heterodimers with VEGF, if both are expressed within the same cell 
[84,85]. This dimer is able to bind to and activate VEGFR1, as well as induce dimerization 
of VEGFR1 and VEGFR2, if both of these receptors are present on the cell’s surface [75]. 
Autiero et al. (2003) report that once PlGF activates VEGFR1, VEGFR2 can then be activated 
through transphosphorylation [86]. 
 
From the above, one can see that the highly coordinated process of angiogenesis involves 
many factors, both promoters and inhibitors. The formation of a mature vasculature 
necessitates this precise spatial and temporal regulation of factors [87] and research towards 
delivering growth factors increasingly aims to recapitulate this process sufficiently. 
 
For researchers to ascertain whether their proposed treatment is capable of bringing about 
angiogenesis, appropriate angiogenic assays need to be devised. Many such assays exist, both 
in vitro and in vivo to enable this testing. However, one of the most pertinent technical 
challenges in studying angiogenesis is selecting an appropriate assay [88]. 
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1.1.5. Studying angiogenesis in vitro 
 
In vitro techniques make it possible to study the proliferation, migration and invasion of ECs 
– all processes that form a part of angiogenesis [89]. In this context, one can study a 
therapeutic’s direct effect on endothelial cells and gain some indication of what one could 
expect in vivo [90].  
 
Two-dimensional (2D) assays can be fast, highly reproducible assays to conduct [91]. An 
example is the proliferation assay, involving the seeding of defined number of cells (e.g. 
endothelial cells) into tissue culture treated wells. After seeding, cells are treated with the 
factors of interest and incubated for a minimum of 18 to 24 hours. Cells can then be counted, 
using a haemocytometer or automated cell counter, and cell numbers compared between 
treatments. In addition, a colorimetric assay can be employed [91]. These include MTT [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] or XTT [sodium 3′-[1-
[(phenylamino)-carbony]-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene-sulfonic acid 
hydrate] assays, which indirectly measure proliferation through measuring mitochondrial 
activity [91–93]. 
 
Cell migration assays can also be carried out, creating a 2D, in vitro model of cellular migration 
after basement membrane degradation, during the angiogenic process. Scratch assays are 
one such example [94]. These involve seeding cells in a monolayer and using an implement to 
create a scratch or “wound”. Growth factors or other proteins of interest can then be 
administered and their effect on the rate of “wound” closure can be monitored. A more three-
dimensional (3D) version of this assay makes use of the Boyden chamber, or modified versions 
thereof [95]. The one side of the chamber contains cells placed on top of a filter (which may 
be coated in an ECM protein) containing pores of a relevant size to facilitate the migration of 
the cell type used. The other side contains the chemoattractant i.e. growth factors of interest. 
The number of cells that migrate through the pores towards the chemoattractant can be 
quantified by staining cells on the underneath of the membrane and/or counting cell in the 
bottom [91,96]. The advantages of this assay include a high level of sensitivity to minor 
changes in chemoattractant gradients [97], and a high reproducibility and short duration, with 
the assay being conducted over a few hours [91]. 
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In vitro cell culture has evolved from culturing cells in a monolayer, to culture conditions that 
are more representative of the in vivo environment, for example 3D assays involving cell 
spheres, consisting of one or multiple cell types, embedded in a matrix. 3D assays have 
allowed for the study of cell-cell interactions, as well as interactions between cells and their 
environment [98,99]. In addition, 3D cell cultures possess a greater stability and longer 
lifespan than 2D cultures. 3D cell spheres can be cultured for at least 4 weeks, as compared 
to 2D culture where cells need to be trypsinised regularly due to confluency [100].  
 
An example of an in vitro angiogenesis assay is the 3D cell-coated microcarrier assay, 
pioneered by Nehls and Drenckhahn in 1995 [101]. In this assay, the outer surface of the 
microcarrier beads are coated with endothelial cells, after which the beads are suspended in 
a fibrin matrix (which can contain other cells in co-culture, for example fibroblasts) [102]. 
Sprouting/invasion into the matrix is then monitored over time and quantified. The downside 
of this assay is that it is very technical – achieving an even coating of cells can be very 
challenging and there will always be some beads that are not sufficiently coated, making 
reproducibility an issue [103,104]. 
 
Pioneered by Korff and Augustin, the spheroid sprouting assay is a challenging but powerful 
in vitro assay for angiogenesis [91,105]. Unlike other assays, the spheroid sprouting assay can 
theoretically, and if necessary, be conducted for several weeks depending on the cell type(s) 
[100,106,107]. Because there is no inflammatory response as there would be in vivo, this 
assay facilitates the study of the mechanisms, both at the cellular and molecular level, 
underpinning the angiogenic process [108]. As with the microcarrier bead assay, this assay 
provides a suitable way in which to study angiogenesis and test potentially pro-angiogenic 
compounds in vitro [108]. 
 
The assay usually involves endothelial cells, particularly human umbilical vein endothelial cells 
(HUVECs) but co-culture spheroids with multiple cell types have been used, embedded in a 
3D matrix [109–111]. Most spheroid sprouting assays are conducted in collagen, but fibrin 
has also been used in the literature [108,109,112].  Spheroid formation relies on the need of 
adherent cells, like those involved in the angiogenic process, to adhere to a substrate [100]. 
Here, they are prevented from adhering to cell culture plastics (as they would in monolayer 
culture) by the addition of methylcellulose to the culture medium. The cells therefore have 
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no choice but to adhere to one another in order to survive [100,113]. This is most commonly 
achieved through a hanging drop method, or through the use of round-bottom culture plates 
that have not been tissue culture-treated [114,115]. In most spheroid assays, the sprout 
length or “extent of invasion” is measured, using micrographs captured, through use of 
computer software, and the number of sprouts is counted [108,109,116]. One can use these 
metrics to compare the effect of added growth factors, for example, or specific culture 
conditions [105]. 
 
The spheroid sprouting assay has many advantages, including the fact that it is more 
representative of the in vivo environment than 2D cell culture assays [105]. It also takes cell 
proliferation, migration, invasion and survival into account. The tunability of this assay is a 
further advantage, with one being able to control and alter experimental conditions to test 
any compound of interest, or the effect of a particular microenvironmental state, in a 3D 
scaffold of choice [108]. As stated by Korff and Augustin (1998), the spheroid cell culture 
model is a very powerful tool, allowing one to study the effect of EC survival/growth factors 
in a 3D environment representative of that found in vivo. 
 
1.1.6. Studying angiogenesis in vivo 
 
Once a therapeutic has been tested in vitro and has been determined to significantly influence 
the cellular processes of interest, like cellular invasion of a matrix, the next step is to assess 
its effects within a living organism. This is a necessary step in validating a potential therapeutic 
and moving towards clinical translation [117]. 
 
These in vivo assays include the embryonic chick chorioallontoic membrane (CAM) assay, the 
corneal angiogenesis assay and the subcutaneous implant model [118,119]. In the latter 
model, sponge-like polyurethane (P.U.) discs or Matrigel plugs have been implanted into the 
subcutaneous space in rodents [120,121]. 
 
In the past, researchers have used CAM assays to study angiogenesis, with the first CAM assay 
conducted by Rous and Murphy in 1911 [119]. Many consider it an in vivo assay, whereas 
some perceive it as an ex vivo model [122,123]. In this assay, the chick embryo takes 21 days 
to develop, with the CAM forming close to embryo development day (EDD) 4 and becoming 
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fully developed at EDD 14 [124,125]. When assessing angiogenesis, the assay usually 
commences on EDD 10 or 11 as this is when vascular expansion in the CAM is at its peak [126]. 
Usually the angiogenic response is evaluated macroscopically by looking at the formation of 
vessels at the site of implantation. This then establishes vascular density, the length of the 
vessels or vessel branching points/mm2. Histological analyses can also be conducted, such as 
staining for CD31 (a marker specific to ECs) immunohistochemically [127]. 
 
As the embryo does not possess a mature immune system, this assay allows for the growth 
of xenografts without them being rejected [127,128]. The CAM assay has also been employed 
in testing biomaterials containing pro-angiogenic factors and/or cells [129]. Although a very 
cost effective, high throughput assay to study angiogenesis, there are a few disadvantages. 
When compared to in vivo assays, the assay has time constraints, with incubation period in 
the chick embryo being limited to between seven and ten days [127]. It is also important to 
recognise that the growth of blood vessels seen on the CAM is almost 2D in nature, and that 
the CAM environment is rather different to what one would find in vivo within an adult animal 
as it is highly specialised for the growth of the chick embryo [130]. The cells that respond in 
this assay are embryonic in nature and are thus already in an activated state. There are also 
drastic changes in vasculature from day to day as the chick embryo develops which need to 
be considered [130]. This assay also often requires animal ethics clearance when chick 
embryos are past a certain developmental stage [131].  
 
An alternate assay is the corneal angiogenesis assay. Originally developed in a rabbit model 
in 1972 by Gimbrone et al. to study tumour angiogenesis, it has since been introduced into 
mice [118,132]. A pocket is made in the cornea, into which the therapeutic is placed. As the 
cornea is avascular and transparent, the premise is that any vasculature seen after applying 
the pro-angiogenic treatment of interest was stimulated as a result of that treatment and can 
easily be identified [91,117]. Quantification can be carried out by measuring the area of vessel 
penetration, chemotaxis of vessels toward the stimulus over time, or fluorochrome-labelled 
substances can be utilised for ease of quantification [117,133]. This assay has been used to 
study the angiogenic effects of growth factors like bFGF and VEGF [118,134]. 
 
Subcutaneous implant assays have also proved useful in assessing the angiogenic potential of 
a growth-factor releasing biomaterial. The degradation of the material can be studied as well 
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as its biocompatibility, in the context of immune and inflammatory responses, and 
cytotoxicity [135]. A specialised approach, specific to our group, involves impregnating P.U. 
discs with the biomaterial, which are placed in pockets under the skin in rats [120]. After a 
period of time, the discs are excised and can be histologically stained for endothelial cell 
markers (e.g. CD31 and CD34) and markers of vessel maturation (e.g -smooth muscle actin) 
[120,136]. 
 
This model has some definite advantages. Referred to as the ectopic subcutaneous implant 
model, it is the least invasive of those used in in vivo tissue engineering research [135]. It also 
creates an environment of defined dimensions (that can easily be excised for analysis) that 
allows the process of angiogenesis to take place by allowing for cellular movement, as well as 
the necessary gaseous exchange and source of nutrients needed for vessel growth. Cells are 
able to move to the implant area and can penetrate the implanted disc, allowing for the 
formation of fibrous, vascular tissue [137,138]. Thus, this a suitable model to use when 
studying a therapeutic’s pro-angiogenic capabilities. 
 
1.1.7. Growth factor candidates for therapeutic angiogenesis 
 
As previously mentioned, growth factors are involved in many important processes, with 
focus here on growth and remodelling of blood vessels [139,140]. There are many growth 
factors and cytokines that are being explored as therapeutic angiogenesis candidates, 
including the aforementioned bFGF and VEGF, as well as tumour necrosis factor-alpha (TNF-
), transforming growth factor-beta (TGF-), placental growth factor 2 (PlGF-2), Ang-1 and 
Ang-2, and platelet derived growth factor (PDGF) [141,142]. The three growth factors of 
interest in this project are bFGF, VEGF and PlGF-2. 
 
bFGF, also known as FGF-2, is an 18 kDa pro-angiogenic protein of 155 amino acids belonging 
to the FGF family, of which there are 18 members in mammals. This was the first successfully 
purified pro-angiogenic factor, isolated in 1984 by Folkman et al. from bovine cornea 
basement membrane [143]. Through binding to their transmembranous tyrosine kinase 
receptors (called fibroblast growth factor receptors or FGFRs), they are able to stimulate cell 
proliferation, migration, differentiation and enhance survival [31,144,145]. There are four 
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known tyrosine kinase FGFRs for these 18 FGFs to bind, namely FGFR1, FGFR2, FGFR3 and 
FGFR4 [146]. bFGF binds to either FGFR1 or FGFR2. 
 
In order for activation to be successful, bFGF must bind to a proteoglycan, specifically heparin 
or heparan sulfate to stabilise the interaction of bFGF with its receptor FGFR1, and upon doing 
so, forms a complex consisting of two bFGFs and two FGFR1s [147][57]. The dimerisation of 
these receptors results in tyrosine kinase residue autophosphorylation. This activates 
downstream signalling cascades which stimulate the survival, proliferation, migration and 
differentiation of ECs [57]. 
 
bFGF has been utilised and studied both in vitro and in vivo. In vitro, it has been shown to 
affect endothelial cells not only by stimulating proliferation and migration, but also DNA 
synthesis and the production of plasminogen activator (PA) [148–150]. Murakami et al. (2008) 
conducted a study in which they inhibited FGF signalling in endothelial cells in vitro and in 
adult mouse and rat endothelial cells in vivo. This group found that disrupting FGF signalling 
resulted in dissociation of adherens and tight junctions, causing endothelial cells to come 
away from the vessel wall. Ultimately, vasculature was lost, elucidating the important role 
FGFs play in maintaining a lasting vasculature [151]. In addition to influencing endothelial 
cells, bFGF also affects SMCs and fibroblasts [152]. 
 
VEGF has become another factor of interest since its use in the pioneering work on hind limb 
ischemia by the Isner Group [39].  As mentioned above, VEGF (originally called vascular 
permeability factor or VPF) has receptors expressed by multiple cells types – e.g. endothelial 
cells, macrophages and keratinocytes – which all play a role in wound healing [141,153]. The 
soluble and membrane-bound form of VEGF usually binds to VEGFR1 or VEGFR2. Neuropilin-
1 (Nrp-1) binds VEGF-A, the 165 amino acid variant produced by alternative splicing [141,142]. 
There are four VEGF isoforms, which range from 121 to 206 amino acids in length and are 
named accordingly [154]. 
 
Upon ligand binding, the VEGF receptors undergo dimerisation and autophosphorylation 
[155]. This leads to the activation of several pathways, namely the Ras/MAP-kinase, the 
PI3K/PTEN/Akt, the Jak/Stat and the PLC-γ/PKC pathways. VEGF’s stimulation of cell 
proliferation occurs through the activation of Akt in the PI3K/PTEN/Akt pathway [155]. It has 
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been suggested that a crosstalk exists between VEGF and other signalling molecules, for 
example sphingosine-1-phosphate (S1P), during angiogenesis [156,157].  
 
VEGF is able to promote the release of von Willebrand factor in the body, stimulate the 
expression of integrins, interstitial collagenase, PA and its receptor, plasminogen activator 
receptor (PA-R), and increase vascular permeability as well as fenestration [141]. One of the 
main issues with the therapeutic use of this growth factor is its short half-life in vivo [158,159]. 
 
PlGF is another member of the VEGF family. The 152 amino acid-long heparin-binding 
isoform, PlGF-2, is of particular interest due to its role in angiogenesis [142,160]. As a result 
of alternative splicing, there are four PlGF isoforms ranging in amino acid length – 131 (PlGF-
1), 152 (PlGF-2), 203 (PlGF-3) and 224 amino acids (PlGF-4) [161–163]. These amino acid 
sequence lengths do not include the 18 amino acid-long signal peptide common to all the 
PlGFs [142]. PlGF-1 and PlGF-3 are the non-heparin binding isoforms, whereas PlGF-2 and 
PlGF-4 possess an additional 21 amino acid long heparin binding domain [161,163,164]. PlGF, 
discovered in 1991 by Maglione et al. in a human placental cDNA library (hence its name), is 
a member of the VEGF family and binds to the same receptors [165]. It has been known to 
bind to Flt-1, but not to KDR, which is thought to mediate most of the pro-angiogenic and pro-
proliferative effects of VEGF. It is to be noted that the binding of PlGF-2 to its receptors is 
heparin dependent [166]. PlGF-2 has also been reported to bind to Nrp-1 [166]. 
 
This growth factor affects multiple cell types – endothelial cells, smooth muscle cells and 
inflammatory cells of the immune system – in order to bring about the growth of new blood 
vessels [167]. PlGF has been shown to be as effective as VEGF but does not cause the 
undesirable side effects like an increase in blood vessel permeability, oedema, hypotension 
or hemangioma formation [167,168].  
 
Research has been conducted in which “naked” PlGF-2 has been delivered. Wu et al. (2015) 
administered PlGF-2 via an intravenous drip over 14 days in a porcine model of myocardial 
ischemia [160]. A significant increase in enhanced myocardial perfusion and contractility was 
seen at rest, and during a period of stress it was noted that no negative side effects were 
observed. It appears that this research group are the first to show the positive effect of PlGF-
2 on myocardial perfusion and systolic function in a clinically applicable model [160]. 
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It is to be noted that there is conflicting data in the literature when it comes to the 
concentrations of PlGF-2 needed to elicit a response, and the type of the response elicited. 
For example, Lang et al. stated that PlGF-2 affects endothelial cell proliferation, where others 
state this is not the case [148,166]. PlGF-2 has been shown to cause the migration of 
endothelial cells [166], however Bompais et al. (2004) found no increase in migration [169]. 
Thus, further research is needed to assess the effects of this growth factor. 
 
1.2. Delivery of pro-angiogenic factors using functionalised, polymeric hydrogels 
 
Although there is a prodigious amount of research into therapeutic angiogenesis approaches, 
delivery is still a major challenge [37,170]. Growth factors can be delivered as recombinant 
proteins by bolus administration. As this has adverse effects, researchers then began to use 
viral vectors to deliver factors. This method too had its disadvantages [171]. Thus, a strong 
case for controlled release using a biomaterial arose [172]. 
 
1.2.1. Bolus delivery of factors 
 
Bolus administration of factors that are not encapsulated (i.e. “naked” factors) within a 
material presents multiple problems. [39]. Usually large doses are delivered, as was done by 
Wang et al. (2013), in a bid to overcome the short half-life of VEGF in vivo [159]. These high 
doses resulted in increased vascular permeability, causing fluid to leak out of the vasculature, 
leading to hypotension. This was confirmed in a study conducted by Hariawala et al. (1996) 
where VEGF (2 mg) was administered into the left coronary ostium in a porcine model of 
chronic myocardial ischemia [173].  
 
Following on from a trial in pigs [174], a Phase-I trial (FGF Initiating RevaScularization Trial or 
FIRST) involving patients with coronary artery disease aimed to further investigate the safety 
and efficacy of recombinant bFGF [175]. In this trial, Simons et al. (2002) also saw hypotension 
occurring after single-bolus intracoronary injection, particularly in the patients given bFGF at 
the highest dose (30 µg/kg) [175,176]. Further indicating the potential for undesirable 
outcomes with a single delivery, the same group reported that there was also trend towards 
both hypotension and tachycardia in patients given high bFGF doses [176]. Higher growth 
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factor doses could result in an imbalance between factors that work in synergism, and it has 
been reported that this approach creates abnormal vasculature with a tendency to regress 
due to cellular and matrix detachment, followed by apoptosis [60,177–179]. In addition, the 
vessels formed during this high-dose administration are not very well perfused [180]. Cooper 
et al. (2001) have also shown that bolus delivery of bFGF can cause proteinuria [181]. 
 
As growth factors play a role in cancer growth, bolus delivery of “naked” factors could also 
unintentionally stimulate distant tumour-containing tissues because the factor is not localised 
to the target site [182,183], although this potentially devastating side effect has not been 
reported. As aforementioned, growth factors delivered “naked” have an extremely short half-
life (VEGF: 35 – 50 minutes [184,185], and bFGF: 45 – 50 minutes [186,187] under normoxic 
conditions). Even under more disease-relevant conditions, half-life is still considered too short 
[188]. In a Phase-II clinical trial involving patients with coronary artery disease receiving VEGF 
by intracoronary infusion, it was reported that by 8 hours post-administration the level of 
VEGF present had already substantially decreased, resulting in only transient VEGF exposure 
[189]. This is usually owing to degradation by proteases in the body [190,191]. Thus, 
therapeutic duration is brief, and the dose that reaches the intended site is low [37,192]. 
 
1.2.2. Controlled release of growth factors 
 
It is now known that localised delivery of these factors, and sustained delivery of low doses 
over time, rather than uncontrolled bolus delivery, are integral to the development of 
functional vasculature [193]. In the physiological context, the ECM is a repository of pro-
angiogenic factors, which are only locally released into the surrounding tissue when needed 
[194]. Often, tissue regeneration takes weeks to months and requires an almost constant 
stimulation by growth factors [172]. On this basis, research focus began to shift towards the 
use of biomaterials, using natural or synthetic polymers as ECM-mimics for controlled growth 
factory delivery [195]. Gene therapy has also been explored as a way of stimulating local over-
expression of the factors, and will be briefly discussed [196–198]. 
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1.2.2.1. Gene therapy 
 
Another means by which researchers have tackled the goal of sustained and targeted delivery 
is through gene therapy, involving the delivery of plasmid deoxyribonucleic acid (DNA) [196–
198]. Though a potentially powerful approach, this extensively investigated area is beyond 
the scope of this thesis. It should be noted, however, that there are possible safety issues 
associated with gene therapy for such prevalent pathologies like ischemic hearts and limbs. 
The commonly used adenovirus vector, when used to treat an ornithine transcarbamylase 
deficiency [199], resulted in the death of one patient as a direct result of the immune 
response mounted against this vector [200]. Furthermore, retroviral-type vectors, used as 
DNA carriers to aid delivery, run the risk of causing insertional mutagenesis. A viral vector was 
used for transgene delivery in a study aiming to treat severe combined immunodeficiency, in 
which suffers possess a mutation in the gene encoding the  chain (c). Hematopoietic stem 
cells were isolated from each patient and transduced in vitro using a defective retroviral 
vector [201]. At first it seemed there were no adverse side effects, however a participant later 
developed acute lymphoblastic leukaemia caused by insertional mutagenesis [202]. 
 
1.2.2.2. Polymeric delivery of growth factors 
 
A mentioned above, sustained delivery of growth factors is pertinent to the formation of 
stable vasculature, and the prevention of high-dose and off-target effects. As viral vectors do 
pose a level of risk, polymeric biomaterials have been considered for sustained delivery. 
These include microparticles, nanoparticles and polymer-coated liposomes, as well as 
injectable hydrogels which polymerise in situ [37,167,203,204]. 
 
Liposomes are composed of mammalian cell membrane phospholipids, making them 
biocompatible [205]. When phospholipids, with their polar heads and hydrophilic tails, are 
immersed in an aqueous solution they arrange into spherical structures consisting of one or 
more lipids bilayers, surrounding an aqueous core [203]. This allows liposomes to envelop 
both hydrophobic and hydrophilic compounds. By using liposomal delivery vehicles, 
bioactivity of protein cargo is prolonged by protecting from extremes in temperature, pH and 
ionic strength [203]. 
 
 31 
In terms of being applied to recombinant growth factor delivery, liposomes have been used 
to orally deliver epidermal growth factor (EGF) for the treatment of peptic ulcers [206,207]. 
They have also been employed to deliver EGF percutaneously for wound healing [208]. In the 
context of myocardial infarction, researchers have delivered VEGF-loaded liposomes [209]. 
However, these were “immunoliposomes” – liposomes altered by addition of anti-P-selectin 
antibodies, P-selectin being a cell-adhesion molecule. This was to aid in selectively targeting 
delivery to the infarct border zone in which a high inflammatory response is present, causing 
an upregulation of P-selectin resulting in leukocyte and stem cell recruitment to the infarcted 
area [210,211]. In this study, lasting improvements in cardiac functioning were observed up 
to 4 weeks post-MI and correlated with increases in vascular density and perfusion [209]. 
 
Although some studies have shown positive results, the use of liposomes comes with 
disadvantages. For example aggregate formation and vulnerability to dissociation by 
enzymes, causing them to leak their contents prematurely [212]. To mitigate this, liposomes 
can be coated in polymers like polyethylene glycol (PEG) as a means of steric stabilisation, 
assisting in creating “stealth” liposomes with improved cargo release kinetics [213–215]. 
Despite this improvement, liposomes possess relatively low growth factor loading efficiency, 
which remains a barrier to use as a delivery vehicle in this context [203]. Unlike cross-linked 
polymeric delivery vehicles, the duration of release from liposomal carriers usually tends to 
be shorter [216]. 
 
Binsalamah et al. (2011) made use of an alternative biomaterial in delivering PlGF-2. This 
growth factor was encapsulated in chitosan-alginate nanoparticles and administered by 
intramyocardial injection. A sustained release was seen over a 5-day period and resulted in a 
significant increase in left ventricular function, vascular density and anti-inflammatory 
cytokines, along with a decrease in scar area formation and levels of pro-inflammatory 
cytokines [167]. 
 
Albumin-alginate microcapsules have also been used as a delivery vehicle to administer 
hepatocyte growth factor (HGF) and bFGF intramyocardially in a chronic heart failure model 
in rats [37]. Through employing the microcapsule delivery mechanism, growth release was 
controlled and the dose needed was substantially decreased. Here, a total of 125 ng HGF and 
500 ng bFGF were delivered, compared to the 10 - 100 g/kg usually administered without a 
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delivery vehicle, which is much higher than the amounts present physiologically. In this study 
the release was successfully confined to the desired treatment area (the left ventricle), 
without leakage in to the systemic circulation [37]. 
 
1.2.2.2.1. Hydrogel-based delivery 
 
Rather than using particles or polymer-coated liposomes, polymer hydrogels can be 
employed for growth factor delivery. A hydrogel can be defined as a cross-linked polymer 
network that retains water due to the presence of hydrophilic groups, similar to the natural 
tissues occurring in the human body [217]. Hydrogels are particularly attractive because they 
possess properties pertaining to both liquids and solids – meaning they are spatially confined 
and yet molecules are able to diffuse out [218]. 
 
There are many benefits to using hydrogels to deliver therapeutics. Their aqueous nature 
assists in maintaining the biological function of the encapsulated substances [219], with their 
cross-linked network allowing for the outward diffusion of the substances while 
simultaneously preventing larger, potentially interfering, molecules from entering the 
hydrogel [220]. Polymerisation of several hydrogels only requires mild reaction conditions, 
such that they can cross-link under biologically relevant conditions without affecting cellular 
viability [221]. Some hydrogels have the added advantage of being injectable, allowing for 
less invasive administration [204,222,223]. 
 
Hydrogels can either be made from natural sources – proteins and polysaccharides extracted 
from living organisms e.g. collagen, gelatin, alginate and fibrin – or from synthetic materials 
like polyvinyl alcohol (PVA) or PEG [172,224–226]. 
 
Natural Hydrogels 
 
Natural hydrogels are known for their good biocompatibility and degradability [172]. These 
hydrogels are successful in mimicking the natural ECM as they are derived from naturally 
occurring ECM components, allowing for cellular attachment, as well as growth factor binding 
and release as would occur in vivo [227–229]. 
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Animal and human clinical trials have taken place using natural hydrogels as delivery vehicles 
[76,230]. Marui et al. (2007) have employed gelatin hydrogels loaded with bFGF in the 
treatment of limb ischemia in a Phase I-IIa clinical trial. This treatment was shown to be safe 
and effective, with most patients showing increased healing of limb ulcers, without raising 
serum bFGF levels and without the need for gene or cell delivery [231]. 
 
Although used in clinical trials, the use of gelatin hydrogels is thought to be limited because 
of the material’s lack of stability and poor mechanical properties when under physiological 
conditions [229]. Xing et al. (2014) have improved the stability and strength by removing 
divalent cations (Ca2+ and Fe2+), while still maintaining the hydrogels cellular attachment 
capabilities [229]. 
 
Fibrin hydrogels were one of the first biomaterials employed in promoting wound healing and 
stopping bleeding [232]. When blood clotting proteins fibrinogen and thrombin are combined 
in the presence of Ca2+, insoluble fibrin forms [233]. This unique means of polymerization 
allows gelation time to be controlled, and by altering reaction conditions one can alter the 
architecture of the hydrogel network [232]. 
 
In a canine model of MI, bFGF was incorporated into a fibrin glue to create a controlled release 
vehicle. Animals in Group I only underwent permanent ligation of the left anterior descending 
coronary artery (LAD), whereas in Groups II and III channels were created after infarct 
induction, transmurally and non-transmurally, respectively. These channels were then used 
to administer the growth factor-containing fibrin glue. Compared to the infarct-only control, 
an increased and persistent angiogenic response was seen, improving cardiac functioning and 
perfusion. However, the one shortcoming of this study was they did not include a control in 
which fibrin without bFGF was administered, or in which bFGF alone was administered 
without fibrin [234]. 
 
Although there are some benefits to the use of natural hydrogels, there exist a few 
disadvantages. These include the variation between the sources from which they are derived, 
and further variation between batches, leading to inconsistencies [235–237]. One cannot 
manipulate the chemistry or physical properties of these hydrogels to provide further spatial 
and temporal cues, which are pertinent for tissue regeneration [122,177,238], to the same 
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extent one can with their synthetic counterparts. By chemically modifying synthetic 
hydrogels, one can provide these cues, making synthetic biomaterials an ideal, and more 
clinically appropriate candidate for use in tissue regeneration [122,239,240]. One can also 
alter the composition of the hydrogel to fine-tune degradation rate, as well as its mechanical 
strength, making synthetic hydrogels like PEG a promising delivery vehicle [217,241]. 
 
Synthetic Hydrogels 
 
As aforementioned, synthetic hydrogels can be made from a variety of polymers, including 
PVA and PEG, as well as polymers like polyacrylic acid and poly-N-isopropyl acrylamide 
(PIPAM), which can also be combined to create new hydrogels [242,243]. 
 
PVA hydrogels have proven to be stable and although historically used as nondegradable 
implants, they can be crosslinked with biodegradable linkages, making them better suited for 
a wider range of biomedical applications [218,244,245]. These hydrogels are commonly 
formed through a process of repeated freeze-thaw cycles, or “cryo-gelation”. This gives rise 
to a highly porous scaffold that allows for diffusion, however in their traditional form these 
hydrogels are ill suited for controlled release of therapeutics [245]. PEG hydrogels, however, 
have shown much promise. 
 
1.2.3. Polyethylene glycol hydrogels for controlled release 
 
PEG monomers can be functionalised with chemical end-groups e.g. vinyl sulfones and 
acrylates (Figure 1) allowing for the formation of complex hydrogels with different 
characteristics in terms of degradation and capacity for cellular invasion [246,247]. 
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Figure 1: The structure of linear and 4-armed polyethylene glycol and the possible 
functionalising end-groups, divinyl sulfones and diacrylates. Image adapted from Zhu (2010) 
[248]. 
 
These PEG hydrogels are created by step-growth Michael-type addition reactions, also known 
as conjugate addition reactions, that are very selective [246,249–252]. Formation of these 
hydrogels involves the “thiol-ene” crosslinking of a dithiol linker, which can be a peptide with 
thiol-containing cysteine residues either end of enzymatically degradable peptide sequences 
(termed “bis-cysteine”) with vinyl sulfone end-groups on the PEG (Figure 2) [249,250,253]. 
PEG functionalised with vinyl sulfone groups will, hereafter, be referred to as PEG-VS. The 
bond formed in this reaction is a stable thioether sulfone bond. Similarly, acrylated PEG 
monomers (PEG-Ac) crosslink with these thiol groups on MMP-recognition peptides 
[247,254,255] to form hydrolytically unstable thioether ester bonds form. PEG-Ac monomers 
will be further discussed in Section 1.3. 
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Figure 2: Mechanism of thiol-ene hydrogel crosslinking, as would occur between PEG-VS 
monomers and peptide crosslinkers like MMP-recognition peptides, as well as between PEG-
Ac and the peptide crosslinkers. Image adapted from Kharkar et al. (2016) [253]. 
 
Utilising these PEG gels has many advantages. They do not require any external stimulation 
to initiate this reaction, and no biologically incompatible leaving groups are generated 
through this reaction [256,257]. These hydrogels also do not elicit much of an immunological 
responses in vivo – they are relatively “biologically inert”, and are able to enhance the 
pharmacology of protein cargo without altering their chemical structure and efficacy 
[30,258,259]. 
 
1.2.3.1. Enzymatic degradation 
 
The Lutolf and Hubbell group developed an enzymatically degradable PEG hydrogel, which 
has since been utilised by other research groups including our own [239,255,260,261]. As 
aforementioned, enzymatically degradable PEG-VS gels are crosslinked using cysteine-
functionalised peptide sequences, that are cleavable by enzymes naturally occurring in vivo 
[120]. This degradation is desirable as it allows for cell invasion and prevents the macrophage-
centric immune response seen with non-degradable PEG hydrogels [262–264]. The 
crosslinking peptide sequences of interest here are those recognised by MMPs. MMPs 
encompass a large group of enzymes, of which there are 23 in the human body [265]. 
 37 
 
The sequence most commonly used is that of collagen type I’s alpha chain substrate site. It 
has been found that substituting the “A” in the sequence (GPQGYIAGQ) for a “W”, giving the 
amino acid sequence GPQGYIWGQ, increases activity [266]. In vivo, this sequence is cleavable 
by a range of different MMPs, and can thus be referred to as “PAN-MMP” [250].  
 
Kadner et al. (2012) showed that enzymatically degradable PEG-VS gels cross-linked with 
MMP-1 specific recognition sequences delivered one week after cardiac infarction in a rat 
model significantly increased wall thickness and fractional shortening, as well as reduced end-
diastolic diameter compared to the control that received saline instead of PEG [255]. Johnson 
et al. (2015) employed the same enzymatically degradable hydrogel in the heart but to deliver 
therapeutics, with the aim of reducing the inflammation. This was achieved by loading the 
PEG gel with coacervates filled with a morphogen (sonic hedgehog) and an anti-inflammatory 
cytokine (interleukin 10) [30]. A preservation of cardiac function was seen after MI, with the 
hydrogel improving coacervate retention post administration and integrating with the heart 
wall. Improved vascularisation was seen after 4 weeks, along with decreased fibrosis. The 
hydrogels themselves also act as a therapeutic, by reducing stress in the ventricle walls (in 
accordance with Laplace’s Law) and restoring the shape of the ventricles [12,260]. 
 
Promoting cellular degradation of these scaffolds by MMPs relies first on cellular adhesion 
and invasion. In order to re-vascularise the area and bring about tissue regeneration, cells 
need to be able adhere to and invade the biomaterial as they would the ECM in the body 
[262]. 
 
Integrins, transmembrane receptors expressed on the surface of cells, mediate cell migration 
and adhesion by binding to ECM proteins (e.g. laminin, collagen and fibronectin) [267,268]. 
Many of these ECM proteins share a 3-amino acid monomeric peptide/integrin binding motif 
– arginine-glycine-aspartate, which is shortened to RGD using the amino acid single letter 
codes [268–270]. This short sequence can be easily synthesised and it has the advantage of 
being relatively stable and less subject to denaturation or degradation in vivo than the 
complete proteins [271]. It can also be incorporated in much higher concentrations than the 
entire sequence [271]. Due to their inert nature, PEG hydrogels do not inherently allow for 
cellular attachment. Therefore, to facilitate cellular adhesion, RGD can be incorporated 
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[218,271,272]. This is achieved with the PEG formulations described here by synthesis of the 
peptide sequence with incorporation of a single cysteine (Figure 3) [262]. 
 
 
Figure 3: The stepwise formation of 4-armed PEG-VS hydrogels by reacting with 
monocysteine-containing cell recognition peptides e.g. RGD (1) and bis-cysteine-containing 
enzymatically degradable peptides e.g. MMP (2) to enable cell attachment and eventual 
degradation of the hydrogel (3). Image adapted by Silva et al. (2009) from Lutolf et al. (2003) 
[262,273]. 
 
1.2.3.2. Mechanical properties 
 
The mechanical properties of hydrogels play a role in mechanotransduction, or the cellular 
conversion of mechanical information obtained from cellular surroundings into biochemical 
signals [274]. This influences how cells spread, migrate and differentiate [275]. Ehrbar et al. 
(2011) have shown that when the matrix has a low stiffness, cells tend to migrate in a manner 
not involving proteolytic degradation [276]. This is usually because hydrogels with a lower 
stiffness have a lower crosslink density as well as channels or defects within them. Thus, there 
are larger spaces for the cells to move through, making cellular migration possible without 
degradation of the surrounding matrix [262]. The higher stiffness matrix however restricted 
migration to that achieved by cellular proteolysis [276]. Thus, when creating a biomaterial 
one must consider matrix stiffness to allow for the desired cell invasion [259]. 
 
Small amplitude oscillatory shear rheometry is conducted to ascertain the mechanical 
properties of a hydrogel. G*, or the complex modulus, is a measure of how stiff an elastic 
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material is. In the case of a hydrogel, the material is both elastic and viscous. Thus, G* is 
divided into two moduli: the storage modulus (G’) and the loss modulus (G’’). When the G’ 
value is greater than the G’’ value, the hydrogel is more solid. When the G’’ value is greater 
than the G’ value, the hydrogels behaves more like a liquid [277]. 
 
1.2.3.3. Functionalisation with heparin 
 
It has been argued that synthetic hydrogels lack an important ECM component involved in 
morphogen presentation – glycans (glycosaminoglycans – GAGs – and proteoglycans – PGs) 
[278]. Glycosaminoglycans are made up of repeating units, which are disaccharide 
derivatives, and can either be nonsulfated or sulfated. Heparan sulfate, as well as its related 
molecule heparin (Figure 4), can attach to serine-containing proteins to form proteoglycans 
[248,279]. Glycans, which are highly negatively charged, are able to aid the diffusion of 
nutrients and through swelling, relieve compressive stresses and prevent tissue from 
collapsing when pressure is applied [280]. 
 
 
Figure 4: The structure of heparin, indicating the disaccharide unit that is repeated through 
the molecule. Image taken from Hung et al. (2012) [281]. 
 
Heparin proteoglycan is found within mast cell granules, whereas heparan sulfate is found on 
the surface of cells and in the extracellular matrix. Heparin is more sulfated and can typically 
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outcompete heparan sulfate for binding to proteins [279]. There are in excess of 100 proteins 
that bind to GAGs through serine residues (with hyalorunan being an exception) to form 
proteoglycans [282,283]. These include proteins involved in cell adhesion molecules (e.g. 
fibronectin and laminin), lipid metabolism (e.g. lipoprotein lipase), coagulation (e.g. 
antithrombin) and many other processes [282]. 
 
Heparin has been widely used for its anti-coagulant effects since 1912 when these properties 
were first described by Doyon [284], with the first formulations suited for human trials only 
being produced in the 1930s [279,285]. However, heparin is more than just an anti-coagulant. 
It was in 1982 that Taylor and Folkman were the first to discover its pro-angiogenic nature 
through the use of the CAM assay [286]. Its pro-angiogenic nature stems from the ability of 
many growth factors to interact with heparin through heparin binding sites – essentially 
clusters of positive charge [279]. Heparin is able to prevent the degradation of these factors 
and prolong their half-life [192]. The presence of heparin has even been found to potentiate 
growth factor activity [287]. For example, as previously described, bFGF signalling involves a 
synergism with heparan sulfate/heparin. After secretion, bFGF is held within the ECM and on 
the cell surface by heparan sulfate/heparin and once released from the ECM, binds to cell 
surface heparan sulfate/heparin. This binding creates a ternary complex, stabilising the 
reaction between the ligand (bFGF) and the FGFR [145,288]. The presence of heparin or 
heparan sulfate also contributes towards VEGF binding to its receptor and confers 
stabilization upon the active conformation of VEGF. These proteoglycans are able to protect 
VEGF from degradation and have been shown to increase the angiogenic response this growth 
factor elicits from endothelial cells [289]. 
 
Heparin thus can be added to hydrogels and other biomaterials to increase their functionality 
[254]. This potentially allows for controlled release of growth factors, preventing their rapid 
clearance, and improving the pharmacology of the proteins without the need to alter their 
structure or alter their chemistry [290]. 
 
Heparin has been employed by our group to modify the surface of porous P.U. scaffolds – 
Bezuidenhoudt et al. used heparin to coat the surface of P.U. discs for subcutaneous 
implantation. They found this to increase vascularisation, without the normally associated 
rise in inflammatory response [136]. This was later taken a step further with the addition of 
 41 
VEGF and PDGF to the heparinized surface of these scaffolds [291]. After 10 days, the dual 
release of these factors was found to increase vascularization within the scaffold, with this 
response lasting a minimum of 2 months post-implantation. Furthermore, heparin was found 
to enhance the angiogenic response elicited by the growth factors [291]. 
 
Very recently, this work has been extended by our group towards incorporation of the heparin 
directly into PEG hydrogels via acrylation of heparin [254]. This was done by reacting a 
heparin/heparan sulfate solution with acrolyl chloride (added by syringe pump) for an hour, 
followed by filtration and, finally, precipitation of the acrylated heparin/heparan sulfate. This 
was then vacuum dried and purified by dialysis against deionized water, and freeze-dried for 
long-term storage [254]. 
 
Although PEG hydrogels with acrylate or vinyl sulfone terminal moieties can potentially bind 
growth factors through interaction with their cysteine residues, this will result in a permanent 
covalent linkage. Thus, bound growth factors either interact directly with invading cells or 
contribute to a chemotactic gradient when released from a degrading hydrogel. The 
incorporation of heparin was postulated to allow for greater binding and enhanced 
chemotactic gradient formation due to the electrostatic nature of growth factor binding to 
heparin. An initial study showed that 8-armed monomeric PEG-Ac hydrogels could bind and 
release VEGF from these hydrolytically degradable hydrogels [254]. An increase in 
vascularization in subcutaneous implants in rats was observed after 4 weeks relative to non-
heparinised PEG hydrogels containing VEGF. Limited release studies were performed on these 
hydrolytically degradable hydrogels. 
 
This 8-arm heparinised hydrogel was investigated in the context of optimising delivery of 
bone marrow mesenchymal stromal cells (BM-MSCs) to the infarcted heart [261]. The fact 
that hydrogel gelation takes place in situ, as a result of the Michael-type addition reaction 
that occurs under normal physiological conditions, confers an advantage to using hydrogels 
in the heart – upon injection, the gelation prevents them from being ejected from the heart 
[257,290,292]. The aim of this study in which BM-MSCs were delivered was to better 
engraftment, and additionally improve the binding and release of the paracrine factors 
secreted by these cells. It was found that heparin-containing hydrogels were better able to 
bind VEGF and bFGF. When delivered along with BM-MSCs, improvements in cell engraftment 
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and retention were seen. Cardiac functioning was also improved, with less remodelling and 
fibrosis taking place [261]. 
 
Thus, these heparinized hydrogels have been investigated in the context of the 8-arm format, 
both for enzymatically and hydrolytically degradable versions. Further work is required on 
growth factor binding and release from the 4-arm formats, which are of interest as they allow 
for less stiff hydrogels to be generated [258], and the range of growth factors studied needs 
to be extended. It would also be of interest to determine the influence of heparin on the 
interaction of cells with growth factors when cells are invading the hydrogel. As described 
above, bFGF interaction with cells is enhanced through its binding to heparin [145,288]. This 
could most easily be examined in a suitable 3D in vitro angiogenesis assay. 
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1.3. Controlling cellular invasion of hydrogels by altering PEG composition 
 
From the previous chapter it has been elucidated that, through chemical manipulation, the 
elastic modulus or stiffness (G’) and general strength of these polymers can be altered to 
create a material that mimics the biological milieu [30,262,293]. By addition of sequences 
that allow for cell adhesion and enzymatic degradation of these scaffolds, thus promoting 
invasion, one further mimics the natural ECM. Thus, ultimately creating a material that can 
enable tissue regeneration in vivo [262]. Through the addition of proteins, like growth factors, 
one can further improve upon the regenerative capacity of these materials through the 
stimulation of angiogenesis [294]. This chapter focuses on a means of manipulating these 
hydrogels to control cellular invasion and, in turn, their replacement by tissue. 
 
As has been elucidated in sections prior, part of what makes PEG such an attractive candidate 
for the delivery of alternative therapies is the control one can exert over its chemistry, and, 
in turn, over its mechanical properties e.g. stiffness [30]. Hydrogel stiffness is influenced by 
the distance between crosslinks and is very important when designing a biomaterial as it 
influences whether cells are able to penetrate the hydrogel [262]. Additionally, the 
mechanical properties of the scaffold have a major influence on cellular behaviour through 
mechanotransduction [295]. It is important in regenerative applications that degradation of 
the scaffold and tissue ingrowth take place simultaneously [239]. A major advance in this field 
was made when the peptide crosslinkers aforementioned were introduced, allowing the 
tissue replacement of the material to be directly linked with cellular proteolytic activity [262]. 
Determining the exact timing of this degradation is also crucial, but complex, and is influenced 
by a wide range of factors. For example, sufficient cellular matrix deposition must occur 
before the scaffold completely degrades. In the case of controlled release, the material needs 
to persist long enough to allow for the sufficient release of its cargo to allow for the 
generation of stable vasculature [296,297]. 
 
Ideally, a scaffold designed for regenerative purposes should allow for preferential invasion 
of desired cell-types that would aid in replacing the temporary scaffold with the desired site-
specific tissue [250]. One would wish to be able to tailor the hydrogels such that only target 
cell types invade in order to ensure optimal cellular functioning [295]. Bracher et al. (2013) 
found that depending on which enzymatically degradable sequence/s one incorporates into 
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the hydrogel, one can intentionally encourage the invasion of specific cell types into the 
scaffold. By using a peptide recognised and cleaved by MMP-14, smooth muscle invasion was 
more pronounced than that of fibroblasts [250]. By altering the amounts of MMP-9 
recognised peptide to a peptide sequence recognised by multiple MMPs (PAN-MMP), cellular 
invasion was controlled in vitro in a spheroid sprouting assay, as well as in vivo [120]. 
 
1.3.1. A novel, multi-modal approach to degradation 
 
Based on the work by Kim et al. (2016), we now wanted to investigate whether we could 
employ 8-arm PEG hydrogels to control cellular invasion using a novel, multi-modal 
degradation system involving hydrogels that are both enzymatically and hydrolytically 
degradable [258]. A drawback of fully hydrolytically degradable gels is that this bulk 
degradation is not cell-driven, i.e. through their migration and movement into the scaffold. 
Thus many researchers turned away from hydrolytically degradable gels to investigate 
enzymatically degradable gels for tissue regeneration [120]. However, if one can combine 
hydrolytically degradable components with enzymatically degradable components, one 
should be able to solve this issue of degradation that is not cell-directed. There is then the 
potential to control cellular invasion and degradation by altering the molar ratios of 
hydrolytically degradable components to enzymatically degradable components. Zhu et al. 
(2015) state that “biomaterial degradation theoretically should be aligned with the pace of 
cell infiltration and neo-tissue formation to allow the structural and functional integration of 
host tissue with tissue developed in the region of the implanted biomaterial” [298]. For 
example, in the context of biodegradable arterial stents, there is a desire to create a stent 
that persists for a sufficient period to allow for vascular wall remodelling, but if the stent 
persists slightly passed this point complications begin to arise [299,300]. Thus, it would be 
ideal if one could tailor the degradation of the biomaterial to the milieu of interest. 
 
Our group has previously shown that one can modulate fibroblast and smooth muscle cell 
invasion rate in our PEG gels [250]. We have also shown that we can control which cell types 
invade and can degrade our PEG hydrogels by utilising cell-type specific MMP sequences 
[120]. However, to the best of our knowledge, no other group has employed a multi-modal 
degradation approach to controlling PEG hydrogel degradation and cell invasion [301]. 
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1.3.1.1. Multi-modal hydrogel chemistry 
 
These hydrogels incorporate the integrin-binding sequence RGD and consist of 8-arm PEG 
monomers functionalised with both vinyl sulfone and acrylate end-groups. As described in 
the previous section, the cross-linking of these hydrogels involves the binding of PEG-Ac 
monomers with thiol groups within the bis-cysteine residues of MMP-recognition peptides 
forming thioether ester bonds [247,254,255]. Like with the 4-arm gels discussed in the 
previous chapter, the PEG-VS monomers are also joined to the thiol-containing peptides but 
by a thioether sulfone bond, which is very stable [260]. The ester bonds between the PEG-Ac 
and the peptide can be broken hydrolytically and would thus be broken first. As this occurs, 
more and more water enters the gels, further increasing the hydrolytic breakage of bonds 
[254,259]. As the PEG-Ac monomers come away, so a network of PEG-VS is left behind that 
can only be enzymatically cleaved at the MMP peptide sequences. 
 
The premise is that upon injection in vivo, the initial structural support needed would be 
provided, but hydrolytic degradation throughout the bulk of the hydrogel would facilitate cell-
directed enzymatic breakdown and thus potentially more rapid cellular invasion would occur 
as the hydrolytically degradable component increases. 
 
Considering all the above, multi-modal degradation may be an attractive approach to tissue 
regenerative scaffolds. Hypothetically, it should allow one to combine the benefits that come 
with both hydrolytic and enzymatically degradable gels, thus creating a scaffold which one 
can exert considerable control over, creating gels even more suited to specific regenerative 
purposes. For example, in the context of wound healing, if dermal grafts degrade too quickly, 
undesired fibrosis takes place rather than a more regenerative form of tissue replacement 
[302]. Thus ,the potential tunability of the breakdown and replacement by tissue of this novel 
hydrogel could allow for its use in many other therapeutic situations, not just in the context 
of myocardial infarction and the cardiovascular system [258].  
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1.4. Study aims 
 
The injectable PEG hydrogel system described above has significant promise as a scaffold for 
regenerative therapies. 
 
The aims of this project were directed toward the optimisation of two critical aspects of the 
hydrogels as related to their regenerative potential: 
 
1. The ability to bind and release growth factors bFGF, VEGF and PlGF-2 in a sustained, 
controlled manner and how this impacts the ability to stimulate angiogenesis. Here 
the hydrogel was to be modified by the covalent addition of heparin, and the effects 
assessed by establishing a suitable in vitro angiogenesis assay. 
 
2.  The degradation rate, and thus replacement by tissue in vivo. The effect of 
modification by exploiting both enzymatic and hydrolytic degradation was to be 
initially determined using the 3D in vitro assay developed in (1.), followed by analysis 
in a subcutaneous implant model in the rat. 
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2. Results and Discussion 
 
2.1. Studies towards establishing an in vitro angiogenesis screening model 
 
Optimising the angiogenic response within regenerative scaffolds is critical. Thus, the utility 
of a cell spheroid-based 3D in vitro angiogenesis assay was investigated as a means of 
analysing the efficacy of modifications that have and will be made to the PEG hydrogel system 
used in our laboratory. After experiments directed towards establishing an in vitro assay were 
completed, an attempt to assay a recent modification, namely the covalent addition of 
heparin into the PEG hydrogel, was carried out. 
 
2.1.1. Rheological analysis of 4-arm 20 kDa PEG-VS hydrogels 
 
The viscoelastic properties of 4-arm 20 kDa hydrogels were determined by small strain 
oscillatory shear rheometry. These hydrogels were formed by cross-linking PEG-VS monomers 
with MMP-1 recognition peptides. Prior to utilisation in an in vitro angiogenesis assay, the 
stiffness and hydrogel-like nature of the hydrogels needed to be established. 
 
 
Figure 5: Rheological analysis of 3.5% 4-arm PEG-VS hydrogels. Frequency sweep from 0.5 
– 5 Hz showing both elastic (G’) and viscous (G’’) components. Results are here represented 
as mean ± SD, n = 9 hydrogels. 
 
The average storage modulus (G’) for 3.5% 4-arm 20 kDa hydrogels was found to be 557 ± 107 
Pa. This storage modulus obtained was somewhat higher than that which our group 
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previously obtained for the same hydrogel formulation of 254 ± 8 Pa [120]. It is hypothesised 
this may be indicative of batch variation for the PEG-VS monomer used. Although not possible 
to empirically test, as only one batch of each was available for this study, reports in the very 
limited literature available on rheological data for this type of hydrogel suggest this to be a 
plausible explanation and also indicate significant variance in storage moduli for similar 
hydrogel formulations [246]. A storage modulus of 290 ± 18 Pa was previously reported for a 
10% 4-arm 20 kDa PEG-VS hydrogel containing RGD (unlike the hydrogels analysed here which 
did not contain RGD) and similarly cross-linked with a MMP-recognition peptide by the 
Hubbell group [303]. However, the Shikanov group reported a modulus of 3.8 kPa for a 5% 4-
arm 20 kDa PEG-VS hydrogel crosslinked with a plasmin recognition sequence [258]. In the 
latter study, influence of this alternative cross-linking sequence may have played a role. It 
should be here noted that the MMP-1 recognition sequence used by the Hubbell only has a 2 
amino acid difference when compared to that used in this study [262], suggesting this 
difference is unlikely to be a cause for the difference observed. Most importantly, the impact 
of removing crosslinking sites by blocking 12% of VS sites using l-Cysteine was found to 
substantially reduce G’ from 3.8 kPa to 1.6 kPa in the Shikanov study [258]. This suggests that 
even minor reductions in modification levels of the PEG monomer termini with vinyl sulfones 
may be, in part, responsible for the discrepancies observed. Further detailed investigations 
to determine the precise cause are needed. For the purpose of this study, this was not 
necessary as only one batch of PEG-VS and one batch of MMP-recognition peptide were used 
throughout the duration. 
 
Frequency sweeps for these hydrogels showed G’ to be stable across the range from 0.5 – 5 
Hz (Figure 5), confirming their hydrogel-like nature. Storage modulus is often nearly 
independent of frequency when the material tested is more hydrogel-like or solid in form, 
whilst a frequency-dependent storage modulus is characteristic of a more fluid-like material 
[304]. The gelled state of these viscoelastic materials was further confirmed by G’ being 
orders of magnitude larger than the loss moduli, G’’ [304,305]. 
 
Thus, the biomechanical properties of the hydrogel were established and the hydrogel was 
found to display hydrogel-like characteristics, allowing for progression to their utilisation in in 
vitro angiogenesis assays. 
  
 49 
2.1.2. Characterisation of isolated human umbilical vein endothelial cells (HUVECs) 
 
An in vitro angiogenesis assay requires the use of endothelial cells. Thus, prior to 
establishment of an appropriate assay which would allow for analysis of the angiogenic 
response in the synthetic PEG hydrogels, an isolation method for primary HUVECs needed to 
be set up in our laboratory. 
 
HUVECs are considered one of the optimal cell types for use in angiogenic models, with 
Maruyama being the first to cannulate the umbilical vein and isolate primary endothelial cells 
[306,307]. Jaffe et al. (1973) then adapted this protocol to use collagenase instead of trypsin, 
and successfully propagated endothelial cells in vitro. This is now widely cited as the standard 
isolation protocol, with researchers adapting it slightly to suit their needs [308]. Advantages 
of utilising umbilical cord tissue include the fact that it is a readily available source, and that 
there are no ethical issues around the isolation of cells from tissue that would otherwise 
usually be discarded as waste. The tissue is easy to collect, without the need for any invasive 
procedures [309]. 
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Figure 6: Assessment of endothelial nature of isolated cells. Bright field micrographs showing 
morphology of isolated HUVECs after A) 24 hours, with slight red blood cell contamination. B) 
Cells at Passage 1 exhibiting the typical cobblestone morphology of endothelial cells. C & D) 
Immunocytochemical staining of HUVECs with anti-CD31 antibodies. Cells counterstained with 
DAPI. Human dermal fibroblasts (HdFbs) were used as a negative control. Scale bar = 100 µm. 
Flow cytometric analysis of isolated HUVECs: histograms showing E) secondary (2°) antibody 
control (2° antibody alone, purple peak) and the primary (1°) and 2° antibody sample (1° and 
2°, turquoise peak), and F) HdFb negative control. 
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A mixture of both larger cells and smaller, biconcave cells are visible on a micrograph from 24 
hours after isolation (Figure 6A). The latter are red blood cells that are flushed out of the vein 
during isolation, but these blood cell contaminants are removed during media changes. After 
3-4 days, the cells reach confluency and can be passaged. Upon approaching confluency, as 
seen for cells at P1 (Figure 6B), the cells start to have the typical cobblestone patterning 
indicative of ECs when cultured in a monolayer [310,311], suggestive of a successful EC 
isolation.  
 
This observation required corroboration and extension by assaying the cells for the presence 
of a surface antigen expressed by ECs, namely Cluster of Differentiation 31 (CD31), by 
immunocytochemistry and flow cytometry. Immunocytochemical staining was conducted 
using a mouse primary antibody against human CD31. The secondary antibody used (goat 
anti-mouse) conjugated with a fluorochrome (Alexa Fluor 488). Thus, the cells showing green 
fluorescence in Figure 6C above could be identified as CD31-positive HUVECS. To confirm this, 
human dermal fibroblasts (HdFbs) were used as a negative control, as they do not express 
CD31. As expected, no green fluorescence was present (Figure 6D). This expression of CD31 
was further confirmed by flow cytometric analysis. A clear shift in fluorescence intensity (FL1-
H) can be seen between the isotype (secondary antibody) control and the sample stained with 
primary and secondary antibodies (Figure 6E), confirming the high percentage of cells that 
were CD31 positive. Here HdFbs were again used as a negative control and produced a peak 
like that of the isotype control, showing no CD31 was present (Figure 6F). 
 
2.1.3. Establishing a spheroid sprouting assay as an in vitro angiogenesis assay within 
the context of synthetic PEG hydrogels 
 
As these synthetic hydrogels, which mimic the ECM, have been and will be used extensively 
in regenerative medicine, a detailed understanding of the angiogenic response to them will 
facilitate their development as regenerative scaffolds. Furthermore, due to their defined 
nature, they can be extensively tuned to determine the influence that parameters such as 
stiffness, cell adhesion site density and degradability, have on angiogenesis in combination 
with pro-angiogenic growth factors. 
 
 52 
Spheroid sprouting assays, as aforementioned, involve the formation of cell spheroids by 
addition of cells to a viscous methylcellulose-containing medium and incubation for 24 hours 
in round bottom, non-adherent culture wells. The spheroids formed are then suspended in a 
3D environment (most commonly collagen or fibrin hydrogels) and allowed to sprout in 
response to pro-angiogenic stimuli [110]. Spheroid-based assays are a widely used method of 
assaying angiogenic responses in vitro in a manner that is more representative of in vivo 
responses than 2D methods [105,108]. Conducting an assay in 3D allows the endothelial cells 
to maintain a phenotype more like that seen in vivo [312–314].  
 
Thus, this assay was chosen to establish an in vitro angiogenic assay in the context of our 
specific synthetic PEG hydrogel, which could then used to study the angiogenic response to 
three growth factors of interest – VEGF, bFGF and PlGF-2 [172] – the latter of which does not 
possess clearly established angiogenic potential [148,166,169]. Our group has previously 
explored the use of a 3D spheroid assay in the context of fibroblast and smooth muscle cell 
invasion into enzymatically degradable synthetic PEG hydrogels [120,250]. However, to our 
knowledge, an angiogenesis spheroid-based assay has not been established for the PEG 
hydrogel. 
 
2.1.3.1. Trouble shooting 
 
In establishing this assay with endothelial cells, a substantial amount of trouble shooting had 
to first be carried out before the effects of the growth factors could be analysed. VEGF and 
bFGF are widely known in the literature to elicit endothelial cell sprouting, thus these growth 
factors were used to assess the potential of this assay in the context of this PEG hydrogel. 
Because there are conflicting findings in the literature surrounding the sprouting response 
elicited by PlGF-2, this growth factor was also assayed to determine whether further insight 
into its in vitro angiogenic potential could be gained [148,166,169]. 
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Figure 7: HUVEC spheroid sprouting assay trouble shooting. A) The charge of the tissue 
culture-treated surface caused hydrogels to spread excessively across the surface, 
substantially reducing the depth of the hydrogel droplet. This caused 1) spheroids to break 
apart (scale bar = 500 µm) or 2) cells to spread along the bottom of the well. Using Sigmacote® 
rendered the surface hydrophobic and allowed hydrogels to bead, forming domes of greater 
depth (scale bar = 100 µm). B) Spheroids sank to the bottom of the hydrogel during 
polymerisation at 37 °C, creating sprouting artefacts. Inverting the 24-well plate for longer 
than 15 minutes, the spheroids would fall to the surface of the hydrogel, preventing sprouting. 
C) Altering the concentration of PEG in the hydrogel from 3.5% (m/v) to 3.25% resulted in 
improved sprouting (scale bar = 100 µm). 
 
Sigmacote® 
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Due to the hydrophilicity of tissue culture treated plates, pre-polymerised PEG solutions 
tended to spread excessively prior to gelation [315] (Figure 7A). This resulted in the hydrogels 
flattening out in the well, causing the spheroids to sink to the bottom of the hydrogel, 
touching the bottom of the plate and thus breaking apart into single cells as the cells begin to 
spread (Figure 7A.1). In less extreme cases, this causes broad sprouts to form and spread 
along the bottom of the plate, rather than within the hydrogel itself (Figure 7A.2). A dome-
shape hydrogel is preferred as it enables most spheroids to be surrounded by gel, creating a 
3D environment with more vertical room for sprouting. To prevent spreading, the 24-well 
plate was siliconised by pre-coating with Sigmacote® (Figure 7A). This altered the surface 
charge, making the surface hydrophobic, reducing wettability and allowing a high contact 
angle to form with the resultant hydrogel droplet [316,317] 
 
Although formation of dome shaped hydrogels did allow for more vertical space for spheroids 
to descend through while the gels set, the spheroids would still tend to sink to the bottom 
and, as above, cause cells to spread along the bottom of the plate instead of within the 
hydrogel. Inversion of the plate while the gels were setting (Figure 7.B) was investigated as a 
means of keeping spheroids remote from the plate surface. However, if the plate was inverted 
for too long, the spheroids all fell to the top of the hydrogel, with some breaching the apical 
surface. This again hindered sprouting and cracked the hydrogel (Figure 8). It was found that 
if the plate was inverted for no more than 15 minutes and then reverted, the spheroids did 
not fall to the apical surface of the hydrogel and were well distributed within the hydrogel 
(Figure 7B). 
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Figure 8: Consequence of inverting spheroid hydrogels for 40 minutes or more. Micrographs 
taken at 24, 48 and 72 hours showing no spheroid sprouting. White arrows indicate cracks in 
the hydrogel caused by the spheroid breaching the hydrogel surface. 
 
Figure 9: Rheological analysis of 3.25% and 3.5% PEG-VS hydrogels. A) Comparison of 
storage moduli of 3.25% PEG-VS hydrogels and the 3.5% PEG-VS hydrogels. Frequency sweeps 
from 0.5 – 5 Hz showing both elastic (G’) and viscous (G’’) components for B) 3.25% PEG-VS 
hydrogels and C) 3.5% PEG-VS hydrogels. Results are here represented as mean ± SD. p < 0.05, 
n=5. 
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Initially, sprouting was conducted in the enzymatically degradable 3.5% 4-arm PEG-VS 
hydrogels that underwent rheological analysis as shown in Figure 5. At this concentration, 
limited sprouting was observed. A reduction in the PEG concentration to 3.25% (m/v) was 
then investigated. This was found to be the optimal percentage for sprout length and now 
allowed the majority of spheroids to sprout (Figure 7C). It is to be noted that hydrogels 
containing less than 3.25% PEG-VS would not polymerise and, thus, could not be utilised in 
this assay. 
 
Rheological analyses were conducted on these 3.25% and 3.5% PEG-VS hydrogels (Figure 9). 
There was a significant difference (p = 0.02) in stiffness between the non-heparinised 3.5% 
and 3.25% PEG-VS hydrogels (average G’ of 445 ± 151 Pa versus 397 Pa ± 69, respectively, n = 
5). This result is as one would expect – the addition of 0.25% less PEG-VS meant that fewer 
crosslinks were formed within the hydrogel per unit volume, thus hydrogel stiffness 
decreased, explaining the improvement in endothelial sprouting seen (Figure 7C). This was 
the last step in establishing this assay. 
 
2.1.3.2. Ability of HUVEC spheroid assay to detect angiogenic responses in PEG-VS 
hydrogels 
 
Initial experiments found that if spheroids were incubated for longer than 72 hours, the 
sprouts would begin to break apart, making analysis challenging (Figure 10).  
 
 
Figure 10: Spheroid sprout disruption occurs at 96 hours: Micrographs (20x mag) obtained 
at 24 and 96 hours of the same spheroid show sprouts begin to break apart, hindering analysis. 
Scale bar = 100 µm.  
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Therefore, it was decided that 72 hours was the time point chosen for image analysis as the 
differences were most pronounced at this time point relative to the control. The angiogenic 
response to the three growth factors of interest – bFGF, VEGF and PlGF-2 – at 72 hours is 
presented in Figure 11. All spheroids were of a similar size (approximately 100 µm diameter) 
and similar round shape, with a very defined edge. By 72 hours, the bFGF- and VEGF-treated 
spheroids had the longest and most numerous sprouts (Figure 11). PlGF-2, at 40 ng/ml and 
100 ng/ml, did elicit sprout growth. However, this response appeared very similar to that seen 
in the control (10% FBS, no growth factors) spheroids. Average cumulative sprout length per 
spheroid and average sprout number per spheroid were the two metrics used to assess the 
angiogenic response. All spheroids present within each hydrogel were included in the 
analysis, except those at the very edge/bottom of the hydrogel, or those that were close to 
other spheroids/had clumped together. This is because spheroids in these locations may have 
a different number and length of sprouts, as well as a different sprout orientation which may 
complicate analysis [116]. 
 
In the majority of literature reporting on angiogenic outcomes of EC spheroid sprouting in 
hydrogels, if reported, 5-10 spheroids are considered per treatment group [109,111,116,318–
321]. A recent study by the original developers of the assay indicated that there is inherent 
variability in the assay [109]. Thus, the following approach was taken to determine that a 
reproducible angiogenic response was being observed. A total of 6-12 spheroids per group 
were assayed in 3 sequential experiments. A verified angiogenic response would be one that 
was found to be significant across all 3 biological repeats. 
 
At 72 hours, bFGF and VEGF both elicited a significant response (p≤0.01) across all three 
biological repeats compared to the control, for average cumulative sprout length per spheroid 
(Figure 11). bFGF elicited average cumulative sprout lengths of 593 ± 277 µm, 403 ± 164 µm 
and 1167.9 ± 309 µm for Experiments 1-3. These cumulative sprout lengths were an average 
of 4-fold higher than the control, which exhibited average cumulative sprout lengths of 206 ± 
113 µm, 133 ± 64 µm and 222 ± 112 µm for Experiments 1-3. VEGF also elicited relative 
increases in average cumulative sprout lengths with lengths of 549 ± 207 µm, 470 ± 249 µm 
and 1367 ± 350 µm for Experiments 1-3. Therefore, on the same weight basis, bFGF and VEGF 
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elicited virtually identical responses, with around 4-fold increases in average cumulative 
sprout length. 
 
Regarding the number of sprouts per spheroid, bFGF-stimulated spheroids had average 
sprout numbers per spheroid of 19 ± 6, 13 ± 5 and 20 ± 3 for Experiments 1-3 respectively. 
This was an average of 2.3-fold more sprouts than the control (average sprout numbers of 10 
± 4, 6 ± 3 and 7 ± 2 were recorded for Experiments 1-3 respectively) and was significant for 
each biological repeat (p<0.01). Again, VEGF followed a similar trend with average sprout 
numbers per spheroid of 16 ± 4, 14 ± 6 and 22 ± 4 for Experiments 1-3 respectively. This was 
an average of 2.4-fold more sprouts than the control and was again significant (p<0.01). 
Therefore, with respect to average number of sprouts per spheroid as well, bFGF and VEGF 
elicited an almost identical response. 
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Figure 11: Spheroid sprouting assay with HUVECs. A) Micrographs showing HUVECs (single 
donour) sprouting over 72 hours. Scale bar = 100 µm. Analysis of spheroid sprouting assays 
with HUVECs (P3-P5) from multiple donours. B) Average cumulative sprout length (µm) at 72 
hours. C) Average sprout number per spheroid at 72 hours. For both B) and C) all growth factor 
concentrations were as follows: bFGF (10 ng/ml); PlGF treatment 1 (40 ng/ml); PlGF treatment 
2 (100 ng/ml); VEGF (10 ng/ml). All treatments contained 10% FBS, including the growth 
factor-free control. ** = p ≤ 0.01 when compared to respective controls. Results are here 
represented as mean ± SD, n = 6-12.  
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Where 3D spheroid-based angiogenesis assays have been used to directly assess the influence 
of VEGF and bFGF, the 3D matrix has been collagen at a concentration of 2 mg/ml. In this 
matrix, bFGF has been found to induce a 3-fold increase in cumulative sprout length after 24 
hours at a concentration of 25 ng/ml (2.5 times higher than that employed here) [322] and 
up to 6-fold after 72 hours at 30 ng/ml [323]. More extensive but still limited data is available 
for VEGF. VEGF was found to increase cumulative sprout length by 2.5-fold after 24 hours 
[322] and around 3.5-fold after 72 hours at 25 and 50 ng/ml, respectively [323]. These 
concentrations are also higher than those used here but in a study that investigated the 
influence of VEGF concentration directly, concentrations from 8 – 642 ng/ml were found to 
induce similar response at 24 hours of around 2.5-fold relative to control [109]. Thus, for VEGF 
and bFGF similar relative increases in sprout length have been observed in collagen as were 
seen in PEG hydrogels here. The absolute responses were more with sprout lengths of around 
800 - 1000 µm in 24 hours that increased to 1750 µm and 2750 µm for VEGF and bFGF 
respectively at 72 hours. 
 
The slightly greater extent of sprouting often seen in collagen hydrogels is most likely the 
result of the lower stiffness of these types of hydrogels – 17 - 100 Pa for collagen [324–326], 
compared to the storage modulus of 397 ±69 Pa for the PEG-VS hydrogels used here. This is 
further reiterated by the fact that sprouting was substantially hindered in the 3.5% PEG-VS 
hydrogels, but by reducing the PEG concentration by 0.25%, and in turn the storage modulus, 
sprouting was improved. Mesh size may also play a role – with collagen having much higher 
mesh sizes of 15 µm on average, but can range from 1 - 20 µm [327] relative to the 20 nm of 
the PEG hydrogels [250]. The mesh sizes in the above natural hydrogels approximate that of 
cellular dimensions, which may allow for cells to move through these hydrogels by both 
mechanical and proteolytic means, whilst cellular invasion into the PEG hydrogels is entirely 
dependent on proteolysis [276]. 
 
Unlike bFGF and VEGF, neither of the two PlGF-2 treatments (40 ng/ml and 100 ng/ml) elicited 
average cumulative sprout lengths or average sprout numbers that were significant when 
compared to the control. The two different PlGF-2 concentrations used were based on the 
following literature: Hoffmann et al. (2013) found 40 ng/ml of PlGF-2 to significantly increase 
cumulative sprout length and sprout number in a spheroid-based angiogenesis assay in 
collagen. This same group conducted a HUVEC migration assay and found PlGF-2 (100 ng/ml) 
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stimulated almost as many cells to migrate as VEGF at the same concentration [328]. Thus, 
these two concentrations were tested. 
 
Average cumulative sprout lengths of 290 ±98 µm, 174 ±163 µm and 179 ±87 µm were found 
for each experiment respectively with PlGF-2 at 40 ng/ml. PlGF-2 at 100 ng/ml elicited average 
cumulative sprout lengths of 326 ±77 µm, 198 ±76 µm and 362 ±120 µm, respectively. On 
average, the average cumulative sprout length of the 40 ng/ml treatment sprouts was only 
1.2 times that of the control, and the average cumulative length of the 100 ng/ml treatment 
sprouts was only 1.6 times that of the control. The 40 ng/ml treatment generated average 
sprout numbers of 12 ±3, 8 ±3 and 5 ±3 per spheroid for Experiments 1-3 respectively. 
Similarly, the 100 ng/ml treatment generated average sprout numbers per spheroid of 15 ±2, 
9 ±3 and 9 ±3. On average, the average sprout number per spheroid for the 40 ng/ml 
treatment sprouts was only 1.1 times the that of the control, and the average sprout number 
per spheroid for the 100 ng/ml treatment sprouts was only 1.4 times that of the control. None 
of these responses to the two PlGF-2 concentrations were significantly increased versus the 
control, but slight increases coupled with the increases observed as the PlGF-2 concentration 
increased, are suggestive of a slight angiogenic response. However, this may be below the 
range of sensitivity of the assay. 
 
Hoffmann et al. (2013) conducted HUVEC sprouting assays but in collagen hydrogels (2 
mg/ml) and only for a duration of 24 hours. This experiment showed that spheroids treated 
with their recombinant PlGF-2 (at 40 ng/ml) produced a significant increase in sprout length 
of about 2-fold, although it was less pronounced than that observed for VEGF where 3-fold 
increases were seen [328]. For sprout number a significant increase almost equivalent to 
VEGF was found. This far more robust response further suggests a possible impact of the PEG 
hydrogel’s greater stiffness and smaller mesh size, although it is not immediately apparent 
why PlGF-2 should be individually impacted. Some have also seen no in vitro angiogenic 
response to PlGF-2 [166,169], further emphasising the wide range of response reported in 
the literature. More in depth studies need to be conducted to investigate this. 
 
Thus, the in vitro angiogenesis assay utilising HUVEC spheroid sprouting has shown promise 
in detecting angiogenic responses in synthetic 4-arm PEG-VS hydrogels. This is important, as 
it should allow for future fine-tuning of these types of hydrogels for regenerative medicine 
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strategies. However, the assay does demonstrate a run-run variability which is undesirable. 
One manner in which to reduce this variability in future is through the use of immortalised 
HUVECs (iHUVECS) in generating spheroids. Heiss et al. (2015) showed that these cells 
displayed less variability in terms of spheroid sprouting, even over multiple population 
doublings, improving the robustness of the assay [109]. 
 
2.1.4. Controlled Release of Growth Factors from 4-arm PEG hydrogels 
 
Our group has recently established a method of covalently attaching heparin into the PEG 
hydrogels [254]. We now wished to utilise the spheroid assay to investigate the influence of 
the attached heparin on the angiogenic potential of the above growth factors. 
 
Heparin was acrylated on the secondary hydroxyls of the polysaccharide with on average 30-
40% of the glucosamine containing disaccharides undergoing acrylation [254]. This acrylated 
heparin can then be coupled into the PEG hydrogel by a Michael addition reaction via the 
sulfhydryl containing peptides used for crosslinking. Prior to analysing the heparin containing 
4-arm monomer PEG hydrogels in the angiogenesis assay, it was considered prudent to 
confirm their ability to entrap and release heparin binding growth factors. This has been 
shown by our group for VEGF and bFGF with the 8-arm monomer hydrogels [261] but not the 
4-arm hydrogels. Additionally, PlGF-2 had not been previously assessed in the context of 
heparinised PEG hydrogels. 
 
To determine VEGF, bFGF and PlGF-2 release from heparinised and non-heparinised 
hydrogels, growth factors were added to the hydrogel constituent mixtures prior to 
polymerisation. Each growth factor was loaded individually. bFGF and PlGF-2 were also 
loaded as a combination to test the effect of adding multiple factors. Once the hydrogels had 
set, they were washed to remove unbound growth factor and placed into iso-PBS. The elution 
rate of growth factors was quantified using ELISA over 20 days. 
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Figure 12: VEGF release from 4-arm PEG-VS hydrogels. A) Comparison of total amount of 
VEGF (ng) bound to heparinised versus non-heparinised hydrogels. B) Comparison of total 
amount of VEGF released (ng) from heparinised and non-heparinised hydrogels. C) Cumulative 
release profile (ng) for VEGF over 20 days. Results are here represented as mean ± SD; n=4 
gels per gel type. ** = p<0.01 
 
Error! Reference source not found.A above shows that, of the 500 ng VEGF added to each 
hydrogel, significantly more bound to the heparinised hydrogels (439 ±7 ng), as compared to 
the non-heparinised hydrogels (350 ±10 ng, p<0.01). The heparinised and non-heparinised 
hydrogels released 61 ±5 ng and 48 ± 8 ng, respectively, within the first day (Error! Reference 
source not found.C). This equates to 13.7% of the total VEGF bound (heparinised), and 13.9% 
of the total VEGF bound (non-heparinised), being released. Thereafter, the non-heparinised 
hydrogels only released an average of 2.5 ng each day until Day 20. This can be seen as the 
release curve flattens after Day 1. Conversely, the heparinised hydrogels released a relatively 
steady amount of VEGF each day, with a daily average of 12.7 ng of VEGF released until Day 
20. The heparinised hydrogels released significantly more VEGF than the non-heparinised 
hydrogels (p<0.01) over the 20 days (Error! Reference source not found.B), with a total of 
304 ± 27 ng being released (61% of total VEGF added) versus 96 ±6 ng (19% of total VEGF 
added), respectively. This is favourable as it shows heparin can be employed to improve both 
the binding and the controlled release of VEGF from these particular hydrogels. 
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The binding of VEGF to PEG hydrogels has been previously investigated by our laboratory in 
collaboration with the Hubbell group [122]. Initially, it had been surmised that only mutant 
VEGF constructs containing unpaired cysteines would be able to couple into the PEG 
backbone. Surprisingly however, it was found that native VEGF165 could couple almost as 
efficiently [122]. 
 
It has been postulated that the unaltered VEGF could potentially bind to PEG-VS via its thiol-
containing cysteine residues although these exist as disulphide cysteines [254,329]. The 
resultant thioether-sulfone bond would be very stable, and would thus not facilitate growth 
factor release until the VEGF is released by enzymatic cleavage [257,330]. A concern therefore 
exists that some structural alterations may result from the permanent coupling of a PEG 
molecule to a critical residue such as cysteine. This concern was part of the rationale behind 
introducing heparin within the PEG-VS hydrogels. But more importantly, it was hypothesized 
that this type of binding would allow for a greater chemotactic effect to be generated with 
VEGF being bound into the hydrogel in a manner analogous to that in which it is incorporated 
into the extracellular matrix [331,332]. 
 
The interaction between heparin and growth factors like VEGF is electrostatic – there exist 
electrostatic forces between the –N and –O sulphated groups within the heparin and the 
amino acid residues lysine and arginine within the growth factors. This electrostatic 
interaction enables a more pronounced growth factor release as the interaction is not 
indefinitely stable, as the formation or dissociation of these interactions is influenced by a 
thermodynamic equilibrium [333]. The fact that the heparin used in these hydrogels is 
acrylated further facilitates growth factor release via hydrolysis of the hydrolytically 
vulnerable ester bond. Such that when the heparin detaches from the PEG through hydrolysis, 
so does the growth factor, allowing for its release in a heparin/growth factor complex 
[254,259]. The use of heparin to bind the growth factors is further advantageous in that it 
mimics the physiological milieu – in the body, growth factors are sequestered in the ECM by 
glycosaminoglycans, thus controlling their local concentration, diffusion, degradation, 
involvement in cell signalling and enhancing their bioactivity [334]. This controlled release 
plays an important role in orchestrating tissue repair and regeneration [335]. Because 
hydrogels already emulate the aqueous nature and mechanical properties of tissues in the 
body, the addition of heparin further enhances their mimicry, boosting their therapeutic 
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potential [336]. The above data also confirm our findings for the 8-arm PEG hydrogels [254] 
and indicates that, indeed, a more pronounced chemotactic effect could be achieved when 
used as a therapeutic angiogenesis vehicle. 
 
After ascertaining that VEGF could be successfully bound to and released from the hydrogels 
in a controlled manner over 20 days, the binding of the other factors of interest, bFGF and 
PlGF-2, was investigated. Furthermore, the effect of combining two growth factors on the 
capacity for binding and release was assayed. This was achieved by creating hydrogels using 
500 ng each of bFGF and PlGF-2 (combination hydrogels). It has been shown in the literature 
that dual delivery of angiogenic factors can elicit more beneficial responses [291,337]. 
 
Similarly to the binding seen with VEGF, significantly more bFGF bound to the heparinised 
hydrogels than the non-heparinised, for both the bFGF alone (436 ±17 ng versus 356 ±16 ng, 
p<0.01) and the bFGF/PlGF-2 combination treatments (429 ±3 ng versus 349 ±19 ng, p<0.01) 
( 
Figure 13A). There was no statistically significant difference in bFGF binding when added 
alone or in combination with PlGF-2 (p=NS). This leads to the conclusion that adding more 
than one growth factor may not significantly impact the total binding of individual factors. 
When considering bFGF release in  
Figure 13B, the non-heparinised hydrogels released 22 ±4 ng (bFGF alone) and 19 ±5 ng (bFGF 
in combination) on Day 1. Similarly, the heparinised hydrogels released 19 ±3 ng (bFGF alone) 
and 16 ±5 ng (bFGF in combination). However, as with the VEGF release seen in Error! 
Reference source not found., much more bFGF was released from the heparinised gels (an 
average of 7 ng/day) compared to the non-heparinised (an average of 0.8 ng/day) over the 
following 19 days ( 
Figure 13B and D). In total, heparinised hydrogels released 150 ±10 ng (bFGF alone) and 148 
±14 ng (bFGF combination), whereas non-heparinised hydrogels released 37 ±5 ng and 35 ±7 
ng, respectively. On average, heparinised hydrogels released 30% of the total bFGF added, 
and non-heparinised gels released 7%. This again demonstrates the effect heparin has on 
enhancing binding and establishing controlled release, thus increasing chemotactic potential. 
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Figure 13: bFGF & PlGF-2 release from 4-arm PEG-VS hydrogels. A) Total amount of growth factor bound to heparinised (Hep) versus non-heparinised 
(Non-hep) hydrogels when bFGF was added alone, and in combination (Combo.) with PlGF-2. Cumulative release profile for B) bFGF and C) PlGF-2 over 
20 days. D) Comparison of total growth factor release from heparinised and non-heparinised hydrogels for bFGF alone and in combination with PlGF-
2. Results are here represented as mean ± SD; n=4 gels per treatment. ** = p < 0.01 when compared to respective non-heparinised hydrogels. 
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Surprisingly, unlike with VEGF and bFGF, the non-heparinised hydrogels bound a small but 
significant amount more PlGF-2 than the heparinised ( 
Figure 13A). Non-heparinised hydrogels bound 482 ±3 ng (PlGF-2 alone) and 472 ±9.6 ng 
(PlGF-2 combination), whereas the heparinised hydrogels bound 465 ± 7 ng (PlGF-2 alone) 
and 445 ±3 ng (PlGF-2 combination). This might suggest that PlGF-2 may have more accessible 
cysteine residues. However, similar trends were seen with the cumulative PlGF-2 release from 
heparinised hydrogels ( 
Figure 13C and D) when compared to VEGF and bFGF. Heparinised hydrogels released 101 
±10 ng (PlGF-2 alone) and 108 ±28 ng (PlGF-2 combination), which is an average of 21% 
release of the total PlGF-2 added. Non-heparinised hydrogels released much less: 4 ±3 ng 
(PlGF-2 alone) and 13 ±5 ng (PlGF-2 combination) on Day 1, which is only an average of 2% of 
the total PlGF-2 added. After Day 1, the non-heparinised hydrogels released no more PlGF-2 
( 
Figure 13C). The heparinised hydrogels released an average of 4 ng/day over the remaining 
19 days. 
 
Despite the difference in binding between the heparinised and non-heparinised hydrogels, 
the heparinised hydrogels still released much more PlGF-2. The lack of release from the non-
heparinised hydrogels is again postulated to be due to the probable covalent nature of the 
bonds formed between the PlGF-2 and the PEG-VS. Although heparin did not increase binding 
here as it did for the other growth factors, chemotactic potential is still enhanced due to 
increased release rate. This must also indicate that a portion of the PlGF-2 bound to heparin 
must have been sequestered away from binding via its cysteine residue to the vinyl sulfone 
moieties. The cumulative released amounts for bFGF and VEGF, where more is released from 
the heparinised hydrogels than the difference between the two hydrogels in total growth 
factor initially bound, also indicates this sequestration occurs with these growth factors. 
 
Compared to the other releases from the heparinised hydrogels, the amount of PlGF-2 
released was the least – 21% release versus 30% (bFGF) and 61% (VEGF). This could be 
because PlGF-2 binds to heparin/heparan sulfate with an extremely high affinity, with a KD of 
approximately 1.5 nM [338]. As aforementioned, VEGF and bFGF have KD values of 60.9 and 
39 nM, respectively [339,340]. The binding of PlGF-2 to heparin has been shown to be so 
strong that Martino et al. (2014) fused PlGF-2’s heparin binding domain onto VEGF, bone 
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morphogenetic protein-2 (BMP-2) and platelet-derived growth factor-BB (PDGF-BB). Thus, 
creating engineered growth factors with a “super affinity” for ECM proteins like heparan 
sulfate, increasing binding by 2- to 100-fold [339]. This may explain why the least amount of 
PlGF-2 was released when compared to the other factors. Therefore, it can be seen that, as 
growth factor affinity for heparin increases (VEGF affinity < bFGF affinity < PlGF-2 affinity), 
binding is enhanced (VEGF binding < bFGF binding < PlGF-2 binding) and growth factor release 
declines, with PlGF-2 having the lowest release, bFGF an intermediate release and VEGF the 
highest release. 
 
The Werner Group have utilised a hydrogel similar to ours, in which heparin activated with 1-
ethyl-3-(-3-dimethylaminopropyl) carbodiimide/N-hydroxysulfosuccinimide (EDC/NHS) was 
bound to the amine terminal end-groups of their 4-arm star PEG, effectively acting as a 
crosslinker [341,342]. However, their growth factors were not incorporated into the 
hydrogels before gelation, as done here, but were bound into the hydrogel after hydrogel 
polymerisation. Unlike the release seen in the figures above, these hydrogels allowed for a 
substantial burst release – over 90% of VEGF and 75% of bFGF were released on Day 1, after 
which the release rate became minimal – 0.33 ng/day (VEGF) and 1.3 ng/day (bFGF) [341]. In 
the experiments presented above, only 20% of the VEGF and 12% of the bFGF were released 
on Day 1. Thus, although these hydrogels were shown to bind VEGF and bFGF as our system 
did, the release appeared less optimal. It is possible that proteins, like growth factors, contain 
amine groups and so undesired binding between the EDC/NHS heparin and these groups 
within the proteins could occur [343]. This would be a more likely occurrence than growth 
factors binding to our PEG via cysteine residues, as cysteine is one of the least abundant 
amino acids within a protein [344]. 
 
It can be concluded that VEGF, bFGF and PlGF-2 could all be bound to the hydrogels, with 
heparin enhancing binding in the case of VEGF and bFGF. Heparinised hydrogels for all growth 
factors could release significantly more growth factor than the non-heparinised over a 
sustained period. Thus, these hydrogels would be suitable delivery vehicles in vivo, allowing 
the desired controlled and sustained release of factors that remain bioactive. 
 
2.1.5. Spheroid sprouting assay in heparinised 4-arm PEG-VS hydrogels 
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As the release data in Error! Reference source not found. and  
Figure 13 show, heparinised hydrogels were very effective at capturing the growth factors, 
allowing for a sustained, controlled release of these factors over 20 days. 
 
Schreiber et al. (1985) and Steffens et al. (2004) state that heparin can potentiate growth 
factor activity and can increase the angiogenic response of endothelial cells [287,289]. The 
electrostatic interactions with growth factors play a role in protein stabilisation/activation 
and also increase cellular receptor affinity [345,346]. Klagsbrun and Baird (1991) showed that 
heparin stabilises bFGF’s interaction with its receptor, allowing a dimer consisting of two 
receptors and two bFGF molecules to form [347]. This leads to autophosphorylation, which 
then triggers the migration, proliferation and differentiation of endothelial cells, ultimately 
leading to angiogenesis [57]. When heparin is not present, bFGF exhibits a greatly reduced 
receptor affinity and thus reduced angiogenic potential [348]. 
 
Based on this, the hypothesis was that incorporating heparin into the hydrogels would mimic 
the physiological scenario, and allow for improved growth factor capture and release, 
potentiating their activity, and thus further promoting sprouting [287,289]. 
 
 
Figure 14: Rheological analysis of non-heparinised and heparinised 3.25% 4-arm PEG-VS 
hydrogels. A) Average storage moduli (G’) of the non-heparinised compared to the 
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heparinised 3.25% PEG-VS hydrogels, p=NS. Frequency sweeps from 0.5 – 5 Hz showing both 
elastic (G’) and viscous (G’’) components for the B) non-heparinised hydrogels and the C) 
heparinised hydrogels. Results are here represented as mean ± SD, n=4. 
 
Rheological analyses were conducted on both heparinised and non-heparinised 3.25% PEG-
VS hydrogels and the results then compared to those obtained for 3.5% PEG-VS hydrogels. 
This was to determine whether altering the amount of PEG would significantly affect the 
viscoelastic properties of the hydrogel. It was found that there was a non-significant drop in 
stiffness after heparin addition, from 397 ± 69 Pa (3.5% PEG-VS) to 300 ± 89 Pa (3.25% PEG-
VS) (Figure 14A). Frequency sweeps for these hydrogels showed G’ to be stable across the 
range from 0.5 – 5 Hz (Figure 14B and C), confirming their hydrogel-like nature. Their gelled 
state was confirmed by G’ being orders of magnitude larger than the loss moduli, G’’ 
[304,305]. These findings indicate that the addition of heparin does not significantly alter the 
viscoelastic properties/stiffness of the hydrogel. This is suggestive that the presence of 
heparin will not influence cell invasion behaviour biomechanically [221,275,349]. This finding 
was perhaps not entirely unexpected, as the relative amount of heparin added was low – 210 
µg heparin per 14 mg PEG, which equates to approximately 1 molecule of heparin per 70 
molecules of PEG, if one makes the assumption that the heparin molecules were of the same 
molecular weight. Although this dose of heparin is considered high in terms of haemostatic 
effect if injected as a bolus, the heparin-PEG is injected such that it gels in situ and only allows 
for controlled release over an extended period. Previous in vivo studies have shown no 
adverse bleeding effects using the same heparinised hydrogel [261,350]. 
 
After concluding that heparinisation does not significantly alter the storage modulus of the 
hydrogel, these heparinised 3.25% PEG-VS hydrogels were employed to ascertain the effect 
of heparin on HUVEC sprouting. 
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Figure 15: Spheroid sprouting assay with HUVECs within heparinised hydrogels. 
Micrographs showing malformed HUVEC (P3) spheroids after 72 hours in both heparinised 
and non-heparinised control hydrogels. Scale bar = 100 µm. 
 
Unlike the spheroids seen in Figure 11, these spheroids did not form properly – they were not 
round and lacked the condensed appearance and defined edge seen with the previous 
spheroids (Figure 15). This was seen for both spheroids embedded in heparinised hydrogels 
and those embedded in the non-heparinised control hydrogels. Furthermore, no sprouting 
was now observed under any conditions, including those previously found to promote 
invasion. Initially, this was thought to be due to the purchasing of a new batch of round-
bottom 96 well plates, although sourced from the same manufacturer. A round-bottom plate 
from the first batch was then used, but the same malformed spheroids were seen. A range of 
HUVECs at different passages and from different donors were used, however this did not 
improve spheroid shape. A new batch of methylcellulose was then ordered as it was thought 
that perhaps the previous batch had deteriorated and did not create a solution of the desired 
viscosity to allow for round, condensed spheroids to form. This again did not improve 
spheroid formation. This apparent irreproducibility of the assay was not resolvable within the 
time constraints of the project. 
 
Although it was not possible to analyse the influence of heparin on the angiogenic potential 
of growth factors in PEG hydrogels, the above experiments did reveal a fragility in the in vitro 
spheroid assay. As the initial studies show that angiogenic effects can be readily discerned in 
this assay, further approaches towards generating a more stable assay will be undertaken in 
the laboratory. These include changing the medium when culturing spheroids within the 
methylcellulose solution from the standard medium containing only 10% FBS to the enriched 
endothelial growth medium [MCDB containing 10% FBS, hydrocortisone (10 mg/L), L-
glutamine (292 mg/L), EGF (10 µg/L) and bFGF (5 µg/L)] as is used in the monolayer culture of 
HUVECs. This would provide a more nurturing environment and could allow for better 
spheroid formation. This approach was previously avoided due to concerns regarding 
interference of the growth factors present in the enriched medium with downstream 
analyses. When generating HUVEC spheroids, Korff et al. (2001) make use of a commercial 
medium by Promocell GmbH containing 2% FBS, EGF (0.1 ng/ml), bFGF (1 ng/ml), heparin (90 
µg/ml), hydrocortisone (1 µg/ml) and 0.4% bovine hypothalamic extract, sold as “Endothelial 
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Cell Growth Supplement” [110]. Some of these additives could be used to further fortify the 
enriched endothelial growth medium in future.  
 
As mentioned above, conducting future assays utilising iHUVECS could reduce the variability 
and irreproducibility as these cells are immortalised, and reduce the effect of passage number 
and donor variability [109]. It is hoped that these further modifications will allow for the 
establishment of a more rigorous in vitro angiogenesis assay that can be used as a tool for 
optimising the PEG hydrogel system as a regenerative scaffold. 
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2.2. 8-arm PEG hydrogels to control tissue invasion 
 
One of the main aims in the field of regenerative medicine is to create a scaffold that can 
successfully guide the regeneration of the damaged tissue [351]. Although it is generally 
thought that fast replacement of a scaffold by functional tissue is optimal, it has become 
apparent that many factors influence this rate and that not all physiological situations will 
have the same requirements [352]. By tailoring the degradation rate of the scaffold, one can 
potentially tailor the rate of cellular invasion to better suit the specific milieu [274,353–355]. 
For example, in a study by Drueke et al. (2004) into full thickness wounds, it was found that 
in dermal grafts, implants that degraded quickly stimulated undesirable fibrosis, which causes 
scar formation [302]. However, when considering vascular grafts, a scaffold with a fast rate 
of degradation prevented calcification as cells were able to infiltrate rapidly [356]. A study 
conducted by our laboratory showed that, in the context of the infarcted heart, functional 
improvement was not seen when rapid hydrogel replacement occurred due to hydrogel 
topography, but a hydrogel shape that allowed for slower degradation was able to return 
function [255]. Thus, it is necessary that the hydrogel replacement rate by tissue can be 
controlled. The studies detailed in this chapter investigate a novel means of achieving such 
regulation in the enzymatically degradable hydrogels by the introduction of increasing levels 
of hydrolytic degradability. 
 
The below studies shifted focus from hydrogels formed from the 4-arm PEG monomers 
(MW:20 kDa) to those from 8-arm monomers (MW:20 kDa). These types of hydrogels have 
been utilised by our group previously as injectable therapies for the infarcted heart 
[30,255,261]. One clear advantage of the increased number of arms in the monomer is that 
they are able to polymerise faster than the 4-arm. In a study by Kim et al. (2016), a time sweep 
test was performed and it was found that the rate at which hydrogel formation took place 
was dependent on the number of arms available for crosslinking [258]. 
 
The aim of the below study was to determine whether tissue ingrowth into these hydrogels 
can be controlled in vivo. The central premise of the approach employed to regulate tissue 
invasion was as follows. A hydrogel formed by crosslinking PEG-VS monomers with bi-cysteine 
containing MMP recognition peptides can only be degraded by cellular-based enzymatic 
hydrolysis of the peptide crosslinker. This does allow for total replacement of the hydrogel by 
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tissue but, as described above [122,262], it would be desirable to be able to speed up this 
process in some instances. Another type of 8-arm PEG monomer with acrylates as arm termini 
(PEG-Ac) can form hydrolytically degradable linkages with the peptide sulfhydryls, again via a 
Michael addition reaction, as aforementioned. Therefore, a hydrogel created with a 
combination of PEG-VS and PEG-Ac monomers, and crosslinked with an MMP-1 recognition 
peptide sequence, would possess some crosslinks which are solely cleavable by cellular 
MMPs, and others which are prone to degradation by both hydrolysis and proteolysis. Thus, 
it was hypothesized that by introducing increasing proportions of the hydrogel that can be 
hydrolytically degraded, in addition to the enzymatically degradable component, an increased 
rate of tissue invasion might be achieved. 
 
As the heparinised form of the PEG hydrogels has increasingly become a focus in our group, 
with its potential for greater regenerative capacity [254,261], heparinised hydrogel 
formulations were utilised. Cellular invasion into the different hydrogels was initially studied 
in vitro using a spheroid sprouting assay, and tissue invasion investigated in vivo using a 
subcutaneous implant assay in rats. 
 
2.2.1. Rheological analysis of heparinised PEG-VS/Ac hydrogel stiffness 
 
To determine whether altering the PEG composition within a hydrogel – i.e. altering the PEG-
VS:PEG-Ac ratios – altered initial hydrogel stiffness, rheological analyses of each hydrogel type 
were conducted. The hydrogels containing only PEG-VS monomers are here referred to as 0% 
PEG-Ac hydrogels, as they contain no acrylate. The 25% PEG-Ac hydrogels contain 75% PEG-
VS monomers, with the remaining 25% of the monomers being PEG-Ac. 50% PEG-Ac hydrogels 
have an equal amount of PEG-Ac and PEG-VS monomers, whereas the 75% PEG-Ac monomers 
contain only 25% PEG-VS. The 100% PEG-Ac hydrogels are formed through crosslinking PEG-
Ac alone with the dithiol peptide. 
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Figure 16: Rheological analysis of 4% 8-arm heparinised PEG hydrogels with increasing 
proportions of PEG-Ac. Average elastic modulus, G’ (Pa), of each type of hydrogel is shown. 
Results are here represented as mean ± SD, p=NS, n=4 hydrogels. 
 
The elastic modulus, or hydrogel stiffness (G’), at a frequency of 1 Hz ranged from 1217 ± 171 
Pa to 1570 ± 290 Pa (Figure 16). Although the G’ values were taken at a frequency of 1 Hz 
(Figure 16), the G’ values do not fluctuate at other frequencies (Figure 17). G’ remains 
relatively constant during the frequency sweep from 0.5 to 5 Hz. As mentioned in the previous 
chapter, for gelled viscoelastic materials such as these hydrogels, one would expect G’ to be 
orders of magnitude larger than G’’, which can be seen below (Figure 17) for all of the 
formulations of 8-arm PEG hydrogels [304,305]. Again, it is here demonstrated that storage 
modulus is virtually independent of frequency when the material is hydrogel-like or solid 
[304]. There was no significant difference in hydrogel stiffness between groups, suggesting 
that replacement of the PEG-VS monomer with PEG-Ac, had no substantial effect on hydrogel 
stiffness and that, biomechanically, the various hydrogels are reasonably similar in nature.  
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Figure 17: Frequency sweeps from 0.5 – 5 Hz. Graphs show both elastic (G’) and viscous (G’’) 
components for the heparinised hydrogels ranging from 0% acrylate (PEG-Ac) to 100% 
acrylate, n=3 hydrogels. 
 
Vinyl sulfones react more selectively and rapidly with thiols through Michael addition than 
acrylates [357]. It was postulated that this difference should not influence the final stiffness 
of the hydrogels as the thiol groups present in the crosslinking peptide sequence are 
stoichiometrically balanced with the sum of the vinyl sulfone and acrylate groups. This is a 
requirement for effective polymerization to occur [246]. Thus, although thiols will react more 
rapidly with the vinyl sulfone end groups, it would be expected that the remaining thiols will 
be available to react with the acrylate groups. The finding that the hydrogels achieve similar 
final stiffnesses indicates that the above postulate is reasonable. 
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2.2.2. 8-arm PEG-VS/Ac hydrogels swelling assay 
 
The hypothesis was that the introduction of increasing amounts of hydrolytically degradable 
ester linkages into the hydrogel should influence the invasion rate of cells into the hydrogels 
after implantation. A greater proportion of PEG-Ac would result in more rapid global 
hydrolysis throughout the hydrogel and this hydrolytic breakdown of the matrix would de 
facto reduce the number of enzymatically degradable linkages needed to be cleaved by 
invading cells. The hydrolytic degradation of links within the hydrogel will increase the 
effective hydrogel mesh size through swelling of the hydrogel [358]. Thus, the swelling of the 
various hydrogels in iso-osmotic PBS at 37 C was determined by weighing hydrogels after 
preparation (W0) and then periodically over a period of 30 days (Wt) , after which the swelling 
ratio (Wt/W0) of the mass of swollen hydrogel, to that of the initial mass at time of 
polymerisation, was determined [359] (Figure 18).  
 
 
Figure 18: 4% 8-arm PEG swelling assay of 0% acrylate (0% PEG-Ac) - 100% acrylate (100% 
PEG-Ac) hydrogels. The experiment was conducted over 30 days, with hydrogels weighed 
after preparation (W0) and at regular intervals after exposure to iso-osmotic PBS (Wt) to 
calculate the hydrogel swelling ratio (Wt / W0). Results are here represented as mean ± SD, n=4 
hydrogels. 
 
Slightly surprisingly, the 0%, 25% and 50% PEG-Ac gels showed a decrease in mass over the 
first day. It is not clear what has caused this apparent deswelling but this initial decrease in 
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mass was found to be reproducible. It is possible that leaching of the heparin that did not 
couple into the hydrogel resulted in a drop in osmotic pressure with concomitant loss of 
water. This loss may then have been subsequently masked by elevated hydrolysis due to 
increasing PEG-Ac concentration. 
 
Of the five different hydrogels, the 100% PEG-Ac hydrogels were the first to degrade. With 
the exception of the 0% PEG-Ac, which was composed only of PEG-VS, all the hydrogels 
showed increased swelling relative to Day 1. This was expected as this hydrogel is only 
enzymatically degradable and has no capacity for hydrolytic degradation. By Day 30, a 17.5% 
increase in weight was seen for the 25% PEG-Ac hydrogels and a 117% increase for the 50% 
PEG-Ac hydrogels. No 100% PEG-Ac hydrogel was visible for weighing at Day 12, indicating 
the hydrogel had degraded to the point of disintegration between Day 10 and 12. Similarly, 
the 75% PEG-Ac hydrogels were seen to degrade between Day 16 and 18.  The remaining 
hydrogels, from 0 – 50% PEG-Ac, persisted until the last measurement on Day 30. 
 
Thus, as predicted, the rate of hydrolysis was proportional to the percentage of hydrolytically 
degradable monomer present. This observation fits with the assumption that degradation of 
crosslinked polymeric hydrogels follows pseudo first-order kinetics, where hydrolysis rate is 
proportional to the number of degradable bonds and that the water concentration is constant 
throughout [360]. It could be seen that the hydrogels with the highest percentage (100%) of 
the hydrolytically degradable PEG monomer (PEG-Ac) degraded first, followed by the 75% 
PEG-Ac gels. The other hydrogels followed the same trend in swelling but persisted over the 
30-day period due to the increasing presence of PEG-VS, the component that forms cross-
links that are only enzymatically degradable. As no MMPs were available to cleave these 
bonds, degradation could not take place. Clearly a stable network, that could persist after 
complete or substantial hydrolysis had taken place, was not present in the 100 and 75% PEG-
Ac hydrogels. Further extension of the hydrolysis period would need to be carried out to 
determine whether the polymer networks formed by the remaining PEG-VS monomers in the 
lower PEG-Ac percentage hydrogels are stable. Importantly, this swelling study demonstrates 
that there will be an increased rate of degradation due to hydrolysis alone, and that this 
should potentially allow for increased cleavage of the remaining enzymatically cleavable 
crosslinks by invading cells. 
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2.2.3. Assessing cellular invasion into 8-arm PEG-VS/Ac hydrogels utilising a spheroid 
sprouting assay 
 
As it had been established that the hydrogels underwent more rapid hydrolysis with 
increasing PEG-Ac content, it was decided to evaluate the influence of this on cellular invasion 
in vitro prior to the ultimate goal of assaying the impact on tissue invasion in vivo. A spheroid 
sprouting assay like that established in Chapter 1 was thus utilised to study endothelial cell 
invasion within the different types of hydrogels.  
 
 
 
 
 
 
 
 
 
 
Figure 19: Spheroid sprouting assay with HUVECs. A) Fluorescent confocal images showing 
sprouting at 120 hours for 0%-100% acrylate (Ac) gels. Nuclei are stained in blue and actin 
filaments in red. Scale bar = 50 m. B) Average cumulative sprout length (nm) at 120 hours 
for 0-100% Ac hydrogels.* = p<0.05 when compared to 0% Ac. Results are here represented 
as mean ± SD, n=7-14 spheroids per hydrogel type. 
 
Based on the swelling assay, one would expect the 100% PEG-Ac hydrogels to show the most 
sprouting over time. This is because these hydrogels would have swelled most rapidly due to 
bonds being broken hydrolytically, and potentially allowed both direct cellular movement, 
through any paths created by the hydrolysis, and a reduced need for peptide crosslinker 
B 
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proteolysis. Paths referred to above were defined previously as physically interconnected 
passages formed by macroscopic cavities and little cracks in the hydrogel into which sprouts 
can extend [276]. It is to be noted that, unlike the spheroid assay presented in the previous 
chapter, this assay was allowed to take place over 120 hours to allow sufficient time for sprout 
formation. This is because these 8-arm PEG hydrogels are made up of a more densely cross-
linked network than the 4-arm PEG hydrogels, potentially resulting in slower sprouting than 
that seen in the 4-arm hydrogels. A higher invasion was already seen in the previously 
presented 4-arm hydrogels by 72 hours (Figure 11), compared to that seen here after 120 
hours. This does indicate that as expected, the 8-arm hydrogels, with their smaller mesh size 
and greater density of crosslinks, do impact on invasion. A longer invasion time was 
investigated, however the sprouts began to break apart, rendering analysis difficult. Why this 
occurs is unclear. 
 
As expected, the 100% PEG-Ac and 75% PEG-Ac hydrogels had the highest average cumulative 
sprout lengths (329 ± 108 µm and 235 ± 93 µm) after 120 hours (Figure 19). When compared 
to the 0% PEG-Ac hydrogels, average cumulative sprout lengths were significant (p<0.05) for 
both the 100% and 75% PEG-Ac hydrogels. The 50% PEG-Ac hydrogels, with an average 
cumulative sprout length of 228 ± 138 µm, were however not significant when compared to 
the 0% PEG-Ac hydrogels. Sprouts within the two hydrogel types with the least acrylate (0% 
and 25% PEG-Ac) were not very long, with average cumulative sprout lengths of 136 ± 179 
µm and 134 ± 140 µm, respectively. Thus, there was a trend towards increased invasion of 
cells as the hydrolytically degradable component increased. It should be reiterated that in all 
hydrogel formulations, the concentration of enzymatically degradable peptide crosslinkers is 
identical. The findings from the spheroid invasion assay suggested that the central premise 
that increasing hydrolytic breakdown would enhance cellular invasion was valid. 
 
2.2.4. Subcutaneous implant model to investigate tissue invasion into 8-arm PEG-VS/Ac 
hydrogels in vivo 
 
After showing with the in vitro spheroid assay that cellular invasion into the various hydrogels 
was augmented by increasing the proportion of PEG-Ac, the rate of replacement by tissue 
ingrowth was assayed in vivo in a rat subcutaneous model. 
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In the subcutaneous implant model, our hydrolytic and enzymatically degradable hydrogel 
hybrids were polymerised within highly porous P.U. discs. These discs allowed for simple 
retrieval of the implanted hydrogel and defined sectioning, staining and analysis [120]. This 
approach thus allows for an accurate quantification of hydrogel replacement by tissue as the 
volume initially occupied by hydrogel is defined [120].  
 
Upon explanting the discs 2 weeks after implantation, the 0% PEG-Ac hydrogel was still intact 
and filled the disc – shown as a uniform pink or purple staining (Figure 20, see chevrons). As 
seen in the H & E stained sections, it appears histological processing may have caused some 
dehydration and wrinkling of the hydrogel within the disc. Very little cellular invasion is 
evident in the discs containing the 0% and 25% PEG-Ac hydrogels at this point. The presence 
of some empty spaces in the 25% PEG-Ac hydrogel, is potentially due to some level of 
hydrolytic break down having taken place. Theses spaces were not seen in the 0% PEG-Ac 
discs. Reinforcing this hypothesis, a greater area of these type of spaces were seen in the 50% 
PEG-Ac discs. Substantially more cellular invasion was able to take place within the 75% PEG-
Ac discs, and further empty spaces were visible. At this 2-week time point, the 100% PEG-Ac 
hydrogels were already fully invaded, as seen in the H & E stained section.  
 
When the equivalent hydrogels were explanted after 4 weeks, further invasion was seen in 
all the discs where there was still capacity for ingrowth (Figure 20 and Figure 21). After this 
period, the 0% PEG-Ac discs again had the most hydrogel remaining. Very little to no hydrogel 
remained within in 50% and 75% PEG-Ac discs. At this time point, a few empty spaces were 
visible within the remaining hydrogel in the 0% PEG-Ac discs. It is possible this is indicative of 
remote cellular proteolytic activity from cells present in the surrounding subcutaneous area. 
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Figure 20: Cellular invasion of P.U. discs impregnated with the different 8-arm PEG hydrogels explanted at 2 weeks and 4 weeks. Explanted discs 
were histologically sectioned and stained (hematoxylin and eosin). The blue dashed line indicates the edge of the P.U. disc. Chevrons indicate 
remaining PEG hydrogel and arrows depict tissue ingrowth. Stars denote the struts of the P.U. discs. Scale bar = 100 µm, n=4. 
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Analysis of the amount of tissue present in the micrographs confirmed complete invasion of 
the 100% PEG-Ac discs at 2 weeks, and indicated that almost complete tissue invasion had 
taken place for the 75% PEG-Ac discs (89 ±6%, Figure 21). The curves of cellular invasion 
generated for 2 weeks and 4 weeks were both sigmoidal in shape (R2>0.99 for both time 
points: logistic A with offset curve fit). The upward shift of the 4-week curve relative to the 2-
week curve, shows that invasion increased in all hydrogel discs, with the exception of the 
100% PEG-Ac containing discs as these were completely ingrown at the earliest time point. 
The largest relative increase in tissue invasion was seen in the 50% PEG-Ac containing discs, 
with the amount of tissue present increasing from 25 ±7% to 92 ±4%, which is almost 
complete replacement of hydrogel by tissue. 
 
 
Figure 21: Tissue ingrowth (%) for each type of 8-arm PEG hydrogel. Results are shown 
after 2 weeks and 4 weeks and represented as mean ± SEM, n=4.  
 
Further than simply assessing cellular invasion, one can evaluate extracellular matrix 
deposition by ascertaining the amount of collagen produced by hydrogel-invading cells [361]. 
Because invasion of the P.U. discs is constrained by the ingrowth volume available, collagen 
deposition could potentially be used to gain further insight into invasion rate. Furthermore, 
it was of interest to determine whether collagen deposition was also temporally regulated by 
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hydrogel acrylate content. The physiological response to the implanted biomaterials seems 
to initiate in a manner similar to that of wound healing, which has three phases: inflammation, 
tissue formation, and tissue remodelling. These tend to overlap rather than occurring one 
after the other [362,363]. During inflammation, immune cells like neutrophils and 
macrophages arrive at the site to clean the wound, removing bacteria and phagocytosing 
material [362]. After a few days, granulation tissue forms consisting of new ECM and blood 
vessels. Fibroblasts migrate in to the wound, differentiate into myofibroblasts, and begin to 
deposit collagen, after which angiogenesis can commence [362]. Thus, collagen deposition 
necessarily follows cellular invasion. 
 
Once this has occurred, cells would infiltrate and begin forming new tissue. At 2 weeks after 
implantation, picrosirius-stained collagen (seen in red in Figure 22) can only be seen outside 
the P.U. discs for the 0% and 25% PEG-Ac hydrogels, with only small amounts being present 
within the disc itself in the 50% PEG-Ac hydrogel. In comparison, more collagen can be seen 
for the 75% PEG-Ac hydrogels, however considerably more was visible in the 100% PEG-Ac 
discs and the staining seemed more intense. Collagen could be seen within all the discs 
explanted after 4 weeks. The collagen content of the 50% PEG-Ac hydrogels at this time point 
appeared comparable to that seen within the 2-week 100% PEG-Ac hydrogels. The 75% PEG-
Ac hydrogels seemed to have a similar amount of collagen present to that observed within 
the ingrowth area of the 100% PEG-Ac hydrogels, however in some areas the intensity of 
staining was diminished. 
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Figure 22: Collagen deposition within P.U. discs impregnated with the different 8-arm PEG hydrogels explanted at 2 weeks and 4 weeks. 
Explanted discs were histologically sectioned and stained (picrosirius red). Scale bar = 100 µm, n=4. 
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It can be seen that, as the acrylate composition of the hydrogels increases, so does 
collagen deposition (Figure 22 and Figure 23). This is because the faster the hydrogel 
degrades, the faster cellular infiltration can take place. The faster cellular infiltration takes 
place, the sooner the cells will start to produce and secrete ECM proteins such as collagen. 
Upon analysing the images in Figure 22, it became clear that the relationship between 
collagen deposition and the PEG-Ac: PEG-VS ratio was sigmoidal in nature (Figure 23, R2 > 
0.99 for 2 and 4 weeks). In relation to the 2-week curve, the 4-week curve altered position 
by shifting up and to the left, with there being a significant increase in collagen deposition 
in all hydrogel groups. 
 
 
Figure 23: Collagen deposition (%) for each type of 8-arm PEG hydrogel. Results are 
shown after 2 weeks and 4 weeks and represented as mean ± SEM, n=4. 
 
One can see there is a slight delay in collagen deposition (Figure 23) relative to cellular 
ingrowth in Figure 21. This is probably due to the sequence in which the wound-healing 
like response occurs. With inflammation occurring first, followed by cellular infiltration 
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and matrix deposition [362]. Although the 100% PEG-Ac discs were fully invaded by 2 
weeks, at this point there was only a 30.5 ±4% collagen deposition. After 4 weeks, these 
explants had a collagen content of 39 ±2%. Similarly, the 75% PEG-Ac hydrogel explants 
were 37 ±2% collagen at 4 weeks. However, image analysis revealed that at 2 weeks, 100% 
PEG-Ac hydrogel explants showed a 77% increase in collagen deposition compared to the 
47% increase (17 ±1% to 37 ±2%) seen in the 75% PEG-Ac hydrogel explants, with this 
difference being significant (p<0.05). Collagen synthesis and deposition appeared to cease 
once 40% of the ingrowth space was taken up by collagen, with both these hydrogels 
reaching this point. It makes sense that the hydrogels with the slowest degradation rate 
(0% PEG-Ac) and thus the least cell invasion will, in turn, show the least amount of 
collagen deposition – 1.6 ±0.2 % after 2 weeks and 8.8 ±3 % after 4 weeks. Therefore, this 
study further validates that the regulation of tissue hydrogel replacement, as well as 
tissue maturation, can be achieved by titration of hydrolytic cleavage points within the 
hydrogel. 
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3. Conclusion 
 
The sustained, targeted delivery of pro-regenerative factors has shown great potential to 
bring about regeneration in various pathological contexts, including CVD and MI-related 
pathologies. Biomaterials like PEG have been employed for such delivery, but also have 
the potential to be used as scaffolds with the ability to guide the process of tissue 
replacement. With each physiological situation possessing its own requirements and 
optimal rate of replacement, a biomaterial like the PEG hydrogel used here with tunable 
biodegradability affords much desired control over the regenerative process. 
 
The viscoelastic properties and hydrogel-like nature of the 4-arm 20 kDa were established 
prior to utilisation of these hydrogels in an in vitro angiogenesis assay. The storage 
modulus was found to be 557 ± 107 Pa by small strain oscillatory shear rheometry, which 
did differ from the literature and was likely due to PEG-VS monomer batch variation. 
 
The next step towards optimising the angiogenic response within the PEG scaffolds was 
to investigate the angiogenic response elicited by the growth factors VEGF, bFGF and 
PlGF-2. Spheroid sprouting assays were established using HUVECs, confirmed as CD31-
positive by immunocytochemistry and flow cytometry, to achieve this. VEGF and bFGF 
were found to elicit significant sprouting responses after 72 hours, with average 
cumulative sprout lengths being 4-fold higher than those of the control. Average sprout 
numbers per spheroid were found to be significantly (2.3 – 2.4 times) higher than the 
control. However, PlGF-2 did not elicit significant increases in sprout lengths when 
compared to the control, or increased sprout numbers. 
 
By conducting growth factor release assays with quantification by ELISA, it was found that 
heparinised PEG-VS hydrogels were able to successfully increase growth factor binding 
and release for all three of the factors of interest over 20 days. It was observed that as 
growth factor affinity for heparin increases (with VEGF having the lowest affinity, followed 
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by bFGF and PlGF-2), binding is enhanced and growth factor release declines – PlGF-2 had 
the lowest release, followed by bFGF and VEGF. Combining two growth factors, bFGF and 
PlGF-2, was found to have no effect on the binding and release of the individual factors. 
 
Further than binding growth factors, heparin itself is also pro-angiogenic and can present 
growth factors in a manner that enhances angiogenesis. Therefore, the effect of sprouting 
within heparinised hydrogels was of interest. These spheroids did not properly form, 
revealing a fragility within the assay. Troubleshooting could not be concluded due to time 
constraints, however it is thought that by fortifying the medium in which the spheroids 
form, this problem may be overcome in future. Utilising immortalised HUVECS may also 
reduce variability, making the assay more robust. 
 
The focus then shifted from the 4-arm PEG monomers to an 8-arm monomer previously 
utilised in the infarcted heart by our group, which is able to polymerise faster and 
possesses increased functionality. Here, the aim was to determine whether tissue 
ingrowth into these hydrogels can be controlled in vivo. Unlike the hydrogels used 
previously, these hydrogels contained varying amounts (0 – 100% m/v) of PEG-Ac and 
PEG-VS monomers, affording the hydrogel varying degrees of hydrolytic and enzymatic 
degradation superimposed on the existent enzymatically degradable background. 
 
Although the hydrogels contained differing concentration of the two monomers, the 
initial storage moduli were found to be similar across all the hydrogels, with G’ ranging 
from 1217 ±171 Pa to 1570 ±290 Pa (p=NS). A hydrogel swelling assay over 30 days 
revealed that the hydrogels containing the most hydrolytically degradable monomers 
(100% PEG-Ac), degraded first between Day 10 and 12, followed by the 75% PEG-Ac 
between Day 16 and 18. The remaining hydrogels, from 0 - 50% PEG-Ac, persisted until 
the last measurement on Day 30, showing that the hydrolytic degradation rate was 
controlled. 
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This swelling assay informed the trends seen when a spheroid sprouting assay was 
conducted within these different 8-arm hydrogels. The hydrogels which degraded the 
fastest (100% PEG-Ac and 75% PEG-Ac), showed the most significant sprouting when 
compared to those that were not able degrade at all (0% PEG-Ac). Importantly, the in vivo 
subcutaneous implant assay which followed showed the rate of tissue replacement was 
proportional to the concentration of PEG-Ac. By altering the proportion of hydrogel 
additionally vulnerable to hydrolysis in the enzymatically degradable hydrogels, the rate 
of tissue invasion was controlled. When assessing collagen deposition, this was also found 
to positively correlate with PEG-Ac concentration. Analysis of collagen allowed for the 
delay in invasion of 75% PEG-Ac relative to 100% PEG-Ac hydrogels to be discerned. 
 
In conclusion, a suitable in vitro angiogenesis assay was established to assess cellular 
invasion within the 4-arm hydrogel system, although it is clear that further modifications 
are required to render this assay more robust in our hands. When heparinised, these 
hydrogels were shown to have improved capture and release of growth factors, further 
adding to the current knowledge of such biomaterials as delivery vehicles. By altering the 
concentration of the two different monomers within the 8-arm hydrogel, control over the 
rate of tissue invasion was achieved. Thus, further optimisation of the PEG hydrogel 
system in several critical areas has been achieved and should allow for increased use of 
this hydrogel in regenerative medicine applications. 
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4. Methods 
 
Recipes for making reagents e.g. cell culture media and PBS can be found in Appendix 1, 
Tables A1 to A8. All specialised reagents, general reagents, consumables and equipment 
used for experiments are detailed in Appendices 2 – 5, Tables A9 to A14, including 
catalogue numbers and supplier information. 
 
4.1. Cell culture 
 
The cells used for in vitro experiments were Human Umbilical Vein Endothelial Cells 
(HUVECs) isolated from waste tissue after obstetric procedures, and were between 
Passage 2 (P2) and P5. Human dermal fibroblasts (HdFbs) were used as a negative control 
for some experiments between P3 and P6. These were obtained from laboratory stocks. 
All cell culture was conducted within a laminar flow hood after sterilization of surfaces by 
UV light exposure for 15 minutes. Surfaces were then further decontaminated using 70% 
ethanol. All items entering the hood were also decontaminated using 70% ethanol. 
 
4.1.1. Cell culture media 
 
Experiments involving HUVECs were conducted in MCDB 131 medium (Table A1, 
Appendix 1), with 10% filtered foetal bovine serum (FBS) and 2% penicillin-streptomycin 
– hereafter referred to as “standard culture medium”. For cell culture prior to seeding for 
experiments, this medium was further supplemented with hydrocortisone (100 mg/L) as 
well as L-Glutamine (292 mg/L), EGF (10 µg/L) and bFGF (5 µg/L) – hereafter referred to 
as “enriched culture medium”. HdFbs were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) with 10% filtered FBS and 2% penicillin-streptomycin – hereafter 
referred to as “standard DMEM medium” (Table A2, Appendix 1). 
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4.1.2. HUVEC isolation 
 
Ethical approval was obtained from the University of Cape Town’s Human Ethics 
Committee (HREC REF: 407/2017), in accordance with the Declaration of Helsinki. After 
obtaining the mother’s written consent, umbilical cords were collected after caesarean 
section at Vincent Pallotti Hospital, Cape Town. 
 
HUVECs were isolated using an adapted protocol [364] as follows: All umbilical cords were 
collected in Collection Medium (Table 1) on the day of birth. The cords were either utilised 
upon arrival at the laboratory or stored at 4 C for 24 – 48 hours, as Jimenéz et al. (2013) 
obtained comparable results when isolating either 24 or 48 hours after birth [307]. All 
cells were isolated under sterile conditions, using sterile drapes, gloves and instruments 
in a laminar flow hood. 
 
Table 1: Media and solutions used during HUVEC isolation 
 
Medium/Solution 
 
Constituents 
   Collection Medium    Medium 199 
   Gentamicin (0.2%) 
 
   Rinse Solution    Medium 199 
   Gentamicin (1%) 
   Heparin (0.2%) 
 
   Collagenase Solution    Collagenase (0.7 g/L or 0.07%)* 
   PBS 
   Inactivation Solution    Medium 199 
   FBS (20%) 
 
* See Table A7, Appendix 1 for recipe and method 
 
The end of the cord was trimmed to remove any blood clots and the umbilical vein 
identified (Figure 24). The vein was then cannulated, securing the cannula by tying a 
suture around it. To remove as much blood as possible, 20 ml of Rinse Solution (Table 1) 
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was then flushed through the vein using a 20 ml syringe into a kidney dish. The 
Collagenase Solution (Table 1) was then flushed through until no more Rinse Solution 
(pink in colour) could be seen flowing out of the vein. The bottom end of the cord was 
clamped and the vein distended with more Collagenase Solution. Once fully distended, 
the top part of the cord was clamped just below the cannula. The cord was massaged 
gently for approximately 2 – 3 minutes to create turbulence inside the vein so as to 
dislodge endothelial cells. The clamped cord was then placed inside a 1 L jar containing 
sterile PBS (Table A3, Appendix 1, pre-warmed to 37 °C) and then placed into a 37 °C 
incubator for 12 minutes. 
 
 
 
Figure 24: Diagram of the umbilical blood vessels and their defining features [365]. 
 
The jar was then removed from the incubator and the cord placed over an open 50 ml 
tube. The clamps were removed and the solution allowed to flow into the tube. The 
Inactivation Solution (Table 1) was then flushed through the vein until no more 
Collagenase Solution (yellow in colour) could be seen exiting the vein. The tube was 
centrifuged at 244 x g for 5 minutes (Megafuge 1.0R, Heraeus Sepatech, Germany). After 
removal of the supernatant, the cell pellet was re-suspended in enriched culture medium 
and pipetted into a collagen-coated well in a 6-well plate. Collagen coating was conducted 
by addition of 400 µl collagen type I (from bovine skin, diluted to 100 mg/L in sterile PBS) 
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to each well for 2 hours at 37 C. The solution was then discarded and wells rinsed with 
an equal volume of sterile PBS three times. When prepared in advance, the plates were 
sealed and refrigerated at 4 C with 2 ml sterile PBS in each well to prevent the collagen 
coating from drying out. 
 
The above process, from the initial cord rinse step, was repeated to obtain a second yield 
of HUVECs which were placed in to another collagen-coated well in the 6-well plate. The 
plate was then placed into an incubator at 37 C with 5% CO2. After 24 hours, wells were 
rinsed with sterile PBS to remove red blood cell debris and fresh enriched culture medium 
was added. 
 
4.1.3. Cell passaging 
 
Once cells were approximately 80% - 85% confluent, culture vessels were rinsed twice 
with sterile PBS, with the volumes as follows: 1 ml for 6-well plate, 2.5 ml for a 25 cm2 
(T25) flask or 5 ml for a 75 cm2 (T75) flask). This was followed by the addition of 0.25% 
trypsin-EDTA (volumes as above) for 2 minutes at 37 °C. Once the cells had lifted, the 
trypsin-EDTA was inactivated with the addition of an equal volume of enriched culture 
medium (with 20% FBS) if the cells were to be passaged further, or standard culture 
medium if the cells were to be seeded for an experiment. This was to minimize any 
influence of growth factors from enriched culture medium on downstream experiments. 
The entire volume was then aspirated and pipetted into a 50 ml tube and centrifuged at 
400 x g for 5 minutes. The supernatant was then poured off and the pellet re-suspended 
in 1 ml enriched culture medium.  
 
A cell count was then carried out as follows: 20 µl of the cell suspension was added to a 
microcentrifuge tube containing an equal volume of Trypan Blue (0.4% m/v). A 
haemocytometer and coverslip were cleaned with 70% ethanol, after which the coverslip 
was placed over the haemocytometer grid and 10 µl of the cell/Trypan Blue solution was 
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loaded under the coverslip. A cell count was then conducted. The four corners of the grid 
were counted, an average was obtained, and the number of cells/ml of media calculated 
as per the equation below: 
 
 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠/𝑚𝑙 = 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑎𝑐𝑟𝑜𝑠𝑠 𝑡ℎ𝑒 4 𝑔𝑟𝑖𝑑𝑠 ×  2 ×
 10 000 
 
The desired number of cells were then seeded for experimental use and the remainder of 
the cell suspension was either added to a flask containing fresh enriched culture medium 
in order to continue passaging the cells, or frozen as detailed below. 
 
4.1.4. Freezing of cells 
 
When primary HUVECs were first trypsinised and counted as mentioned above, at least 
one vial of cells was frozen to create a stock. Cells stocks up to P4 were created. This was 
conducted in the following manner:  
 
Firstly, a 15% (v/v) DMSO stock was prepared in enriched cell culture medium and frozen 
in 1.5 ml aliquots. Before trypsinisation, an aliquot was thawed in the fridge and kept cold. 
Cells were trypsinised and centrifuged according to the protocol mentioned above. A cell 
count was carried out and the cell solution diluted, if needed, to create a solution with 
approximately 500 000 cells per 600 µl. This volume was then added to a cryovial, 
followed by the slow addition of an equal volume of 15% DMSO, and mixing by pipetting 
up and down, to achieve a final DMSO concentration of 7.5%.  
 
Due to the sensitive nature of these endothelial cells, a cell freezing device (Mr. Frosty, 
Nalgene, MA), filled with isopropyl alcohol at room temperature, was used to freeze the 
cells. This controls cell freezing to a rate of 1 C per minute. Once the DMSO was mixed 
in, the cryovial was placed straight into the Mr. Frosty and frozen at -65 C overnight. 
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The following day, the cells were removed from the -65 C freezer, and cryovials placed 
into a liquid nitrogen storage tank (- 196 C) for long-term storage. 
 
The same procedure as above was followed when creating frozen stocks of surplus HdFbs. 
  
4.1.5. Thawing frozen HUVECs and HdFbs 
 
The desired cryovial was removed from the liquid nitrogen tank and quickly thawed in a 
37 C water bath. The contents were then placed into a T25 or T75 flask, depending on 
the number of cells in the vial, containing enriched culture medium (HUVECs) or standard 
DMEM medium (HdFbs) with 20% FBS, rather than the standard 10% FBS used during 
passaging. The flask was then placed into the incubator, with a change of medium to that 
containing 10% FBS taking place 24 hours later. 
 
4.2. Assaying CD31 expression of HUVEC isolates 
 
The endothelial cell phenotype of all cell isolates was determined by immunostaining for 
the endothelial-specific marker CD31 and assessed by immunocytochemistry or by flow 
cytometry. 
 
4.2.1. Immunocytochemical staining of cells 
 
4.2.1.1. Collagen coating coverslips 
 
Round coverslips (12 mm diameter) were placed into the wells of a 24-well plate and 
coated with 100 µl collagen type I from bovine skin (100 mg/L) as described for the 
collagen coating of the 6-well plates above. After rinsing, the coverslips were covered 
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with 500 µl sterile PBS and the plate was stored at 4 C until the day of cell seeding. Before 
cells were seeded, the plate was brought to room temperature. 
 
4.2.1.2. Seeding and staining cells 
 
The optimal dilution for both primary and secondary antibodies was initially established. 
HUVECs were cultured to P4 and trypsinised as aforementioned. HdFbs were used as a 
negative control. 
 
A cell count was conducted and 75 000 cells seeded onto the collagen-coated coverslips 
in a 24-well plate with a total of 400 µl of the respective media. After incubation at 37 C 
for 24 hours, the cells were fixed using 1 ml cold methanol for 15 minutes. The seeded 
coverslips were then blocked with 1% BSA-PBS for 45 minutes to prevent non-specific 
antibody binding and then washed four times with 1 ml PBS for 5 minutes. 400 µl of the 
primary antibody (monoclonal mouse anti-human CD31) was added at the following 
concentrations: 1:500, 1:1000 and 1:2000 and incubated at 4 C overnight. The wash 
steps were then repeated to remove unbound antibody. The fluorescently tagged (Alexa 
Fluor 488) secondary antibody (goat anti-mouse) was added at concentrations of 1:2000, 
1:4000 and 1:8000 and incubated for 30 minutes at room temperature in the dark. The 
wash steps were again performed. Coverslips were carefully lifted using curved forceps 
and placed cell-side down onto a microscope slide with a drop of Fluoroshield containing 
DAPI nuclear stain.  
 
Cells were then immediately viewed using a Nikon 90i microscope and micrographs 
captured at 400x magnification. The optimal primary antibody dilution was found to be 
1:500, and the optimal secondary antibody dilution to be 1:2000. These dilutions were 
then used to assay all HUVEC isolates. 
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4.2.2. Flow cytometry analysis 
 
HUVECs and HdFbs were trypsinised as previous described, however, instead of 
inactivating the trypsin with a cell culture medium containing FBS, a solution of PBS, 10% 
FCS and 1% sodium azide (Solution I) was used. The cells were then split into two separate 
microcentrifuge tubes – one to receive only secondary antibody (secondary antibody 
control) and one to receive both primary and secondary antibodies. The microcentrifuge 
tubes were centrifuged at 800 x g for 3 minutes. After resuspending with 300 µl of ice-
cold Solution I, the cells were labelled with an equal volume of primary antibody 
(monoclonal mouse anti-human CD31 at 1:500 dilution, diluted in 1% BSA-PBS). The tubes 
were wrapped in foil and incubated at room temperature for 30 minutes. Cells were then 
centrifuged as above, and the pellet resuspended in 450 µl ice cold PBS. This was repeated 
3 times. The secondary antibody [goat anti-mouse: AlexaFluor 488 F(ab’) 2 fragment of 
goat anti-mouse IgG (H+L)] was then diluted (1:1000) in a 1% BSA-PBS (Solution II). After 
the last centrifugation, the pellet was resuspended in 450 µl Solution II. After incubation 
at room temperature for 30 minutes, cells were centrifuged 3 times as above. After the 
last wash, the pellet was resuspended in Solution III – PBS containing 3% BSA and 1% 
sodium azide.  
 
CD31 expression was detected in the HUVEC and HdFb samples using a Beckon Dickson 
FACSCalibur flow cytometer system and shown as a shift from the mean fluorescence 
measured. A count of 10 000 cells was conducted, and cells gated based on forward and 
side scatter (FSC and SSC, respectively) to exclude non-viable cells and any debris within 
the samples. 
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4.3. PEG hydrogels 
 
4.3.1. Preparation of the PEG monomers 
 
4-armed and 8-armed PEG-OH monomers, both with a molecular weight of 20 kDa, were 
utilised to form PEGs with vinyl sulfone (PEG-VS) and acrylate (PEG-Ac) termini. This was 
conducted by the Polymer Laboratory of the Cardiovascular Research Unit at UCT, using 
a previously described protocol [254]. The 8-arm PEG-Ac was purchased from JenKem 
(TX). 
 
In brief, the protocol for all PEG-VS was as follows: PEG-VS was created by deprotonation 
of the PEG-OH using sodium hydride, followed by addition of divinyl sulfone (C4H6O2S), in 
excess. To quench any residual sodium hydride, acetic acid was added. This was then 
followed by precipitation in ether, repeated a total of three times. The PEGs were then 
frozen in 50 ml centrifuge tubes. The tubes were covered with Parafilm, into which holes 
were made to allow vacuum removal of air/vapours, and placed into the freeze dryer flask 
attachments. The samples were then freeze-dried overnight, after which they were 
stored at -20 °C. The desired amounts of PEG were weighed out as needed from this stock. 
 
4.3.1.1. Lyophilising PEG 
 
The 4-arm and 8-arm PEGs were reconstituted in sterile Nanopure water to a 
concentration of 2% (m/v). This was then aspirated into a 20 ml syringe and filtered into 
a 50 ml centrifuge tube using a syringe filter unit (pore size 0.2 µm) so as to sterilise the 
PEG for cell culture. Aliquots were made so that each tube contained 5 mg or 10 mg of 
PEG. The lids of the tubes were then tightly closed and the tubes immersed in liquid N2 to 
flash freeze the PEG. The lids were then opened slightly and the tubes placed into the 
freeze-dryer flasks and inserted into the freeze dryer. The samples were left to freeze-dry 
overnight, after which they were stored at -20 °C. 
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4.3.2. Preparation of the acrylated heparin 
 
Heparin molecules containing OH-termini were deprotonated and acrylated with acryloyl 
chloride in the same manner mentioned above, to form acrylated heparin (Hep-Ac) [254]. 
1H NMR was conducted by the Polymer Laboratory, and it was found that 40% of the 
heparin disaccharide units were acrylated through this process. 
 
4.3.3. Formation of the 4-arm PEG-VS hydrogels  
 
These PEG hydrogels consisted of 4-arm PEG-VS monomers and an MMP-1-degradable 
peptide linker sequence (here referred to as MMP-1 peptide) in a molar ratio of 2:1, 
respectively. For experiments where cells were embedded in the PEG hydrogel, cellular 
adhesion was required. To achieve this, RGD was added in a molar ratio of 12.5 PEG:1 
RGD. Some hydrogels were heparinised by the addition of the Hep-Ac aforementioned. In 
these hydrogels, Hep-Ac was added as 1.5% (m/m) of the PEG. 
 
“Master mixes” of all the constituents were created to limit variability between hydrogels. 
Each individual hydrogel was then pipetted from this homogenous mixture. When making 
up the hydrogel for experiments, the PEG and RGD were first reconstituted from freeze-
dried powder with 0.3 M triethanolamine (TEOA, pH 7.4, see Table A8, Appendix 1). The 
reconstituted PEG and RGD were then combined in their respective amounts – see Table 
2 below for an example of the volumes used to create a 100 µl 4-arm PEG hydrogel. 
Volumes were adapted as needed. The solution was incubated for 30 minutes in a 37 °C 
water bath, after which the required amount of TEOA was added. The MMP-1 peptide 
was also reconstituted from freeze-dried powder with TEOA, after which it was the last 
constituent added to prevent the hydrogel from setting too soon. If desired, heparin (Hep-
Ac) could also be added. After addition of all the constituents, the hydrogels had a final 
PEG concentration of 3.5 or 3.25% (m/v). 
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Table 2: Making a 3.5% 100 µl 4-arm PEG-VS hydrogel 
Hydrogel constituents Initial stock 
concentration 
Volume (µl) 
PEG-VS 10 mg/100 µl (10%) 32.5 
RGD 0.1 mg/ 60 µl 7.2 
Heparin* 1.5 mg/100 µl 3.24 
TEOA 0.3 M 40.96 
MMP-1 peptide 1 mg/ 23.8 µl 16.1 
Total volume 100 µl 
*For non-heparinised hydrogels, the heparin volume was replaced by TEOA 
 
4.3.4. Formation of the 8-arm PEG-VS/Ac hydrogels  
 
For these 8-arm PEG hydrogels, the MMP-1 peptide and PEG monomers were combined 
in a molar ratio of 4:1, respectively. When cellular adhesion was needed, RGD was added 
in the same 12.5:1 molar ratio as for the 4-arm PEG hydrogels aforementioned. If desired, 
Hep-Ac could be added at the same concentration as above. To create hybrid PEG-
Ac/PEG-VS hydrogels, 25%, 50%, 75% or 100% of the PEG-Ac volume was replaced with 
PEG-VS. These hydrogels were made up to a final PEG concentration of 4% (m/v). 
 
Table 3 below shows an example of the volumes used to create a 100 µl 8-arm 25% PEG-
Ac hydrogel. Volumes could again be adapted as needed. 8-arm PEG hydrogels containing 
25% PEG-Ac and 75% PEG-VS – referred to as 25% PEG-Ac hydrogels – were created using 
the stock concentrations and volumes in Table 3. Using the same stocks, PEG-Ac and PEG-
VS ratios were altered to create the other hydrogels (Table A5, Appendix 1). When 
hydrogels were prepared for the in vivo subcutaneous implant study, iso-PBS (Table A4, 
Appendix 1) was used to reconstitute constituents and make the hydrogels up to a final 
volume. 
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Table 3: Making a 100 µl 8-arm 25% PEG-Ac hydrogel 
Hydrogel constituents Initial stock 
concentration 
Volume (µl) 
8-arm PEG-VS 10 mg/100 µl (10%) 30 
8-arm PEG-Ac 10 mg/100 µl (10%) 10 
RGD 0.1 mg/ 60 µl 9.84 
Heparin* 1.5 mg/100 µl 4 
TEOA/Iso-PBS 0.3 M 13.16 
MMP-1 peptide 1 mg/ 23.8 µl 33 
Total volume 100 µl 
 
4.3.5. Rheological analyses of PEG hydrogels 
 
For rheological analyses of PEG hydrogels, flat discs are optimal [246]. Hydrogels were set 
between two glass plates with spacers. First, the glass plates were siliconised by coating 
them with Sigmacote®. The plates were air dried, rinsed with distilled water and buffed 
dry with tissue paper. 4 glass coverslips were placed on either side of the plates, giving 
the hydrogels a thickness of approximately 4 mm. 
 
The 4-arm and 8-arm PEG hydrogels were made in the same manner as described above, 
with each hydrogel 100 µl in size. After adding all constituents together, the hydrogels 
were pipetted onto a glass plate, after which the second plate was lowered and used to 
sandwich the hydrogels. To keep the glass plates together, foldback office clips were used 
on either side. 
 
The hydrogels were left to set at room temperature for one hour and then immersed in 
distilled water overnight. The plates were carefully separated using a blade, and hydrogels 
lifted off the glass plates using a siliconised glass coverslip. 
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Once lifted, the hydrogels were placed into 35 x 10 mm siliconised petri dishes containing 
distilled water and equilibrated for 1 hour. 
 
Small strain oscillatory shear rheometry was conducted in a similar manner to that 
described by Goetsch et al. (2015) using a Kinexus Pro rheometer (Malvern Instruments, 
U.K.), with the upper geometry being a flat plate with a 20 mm diameter. The lower 
geometry was set to 37 °C with the rheometer hood closed. Once it had reached 
temperature, the hood was opened and a hydrogel placed onto the lower geometry. The 
upper geometry was lowered onto the hydrogel until a normal force (N) of approximately 
0.5 N was reached, with the gap being 0.5 – 0.65 mm for all hydrogels analysed. A 
frequency sweep was conducted from 0.5 to 5 Hz with 1% strain to obtain the storage (G’) 
and the loss (G’’) moduli. The G’ and G’’ values of the hydrogels analysed were 
represented and compared at 1 Hz.  
 
4.3.6. Swelling analysis of heparinised 4% 8-arm PEG-Ac/PEG-VS hybrid hydrogels 
 
The constituents for heparinised 4% 8-arm PEG-Ac/PEG-VS, were combined as described 
above. 20 µl hydrogels were formed on flattened Parafilm and allowed to set for one hour 
at 37 °C (n=4 per hydrogel type). The hydrogels were weighed to establish their initial 
weights. They were then swelled in microfuge tubes containing 300 µl iso-osmotic PBS 
with 0.02% sodium azide and 2% penicillin/streptomycin at 37 °C in a shaking incubator 
set to 50 revolutions per minute (RPM) for 30 days. The hydrogels were weighed at 
regular intervals over this 30-day period. 
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4.4. Establishment of of HUVEC spheroid sprouting assays 
 
The spheroid sprouting assay pioneered by Korff and Augustin [105], conducted in 
collagen hydrogels, was here adapted to study invasion into our PEG hydrogels. 
 
4.4.1. Siliconising 24-well plates for use in spheroid assays 
 
To create hydrogel droplets, the 24-well plates needed to be siliconised. This was done 
by addition of Sigmacote® to each well in the laminar flow hood. The Sigmacote® was left 
for a few seconds and then removed. The plates were then inverted onto paper towel and 
left to dry inside the laminar flow hood overnight. The wells were then washed with sterile 
Nanopure water, and again inverted and left to dry overnight. The plates were then 
placed into sterilisation bags and sterilised using ethylene oxide. 
 
4.4.2. Preparation of methylcellulose 
 
MCDB 131 medium was prepared with a pH of 7.4 and filter sterilised. Methylcellulose 
(3.6 g) was weighed into a 500 ml Schott bottle containing a magnetic stirrer bar and 
sterilised by autoclaving. 150 ml of the sterile medium was poured into a sterile 
measuring cylinder. The cylinder was sealed with foil and placed into a 60 °C water bath 
for 15 minutes. This warmed medium was then added to the methylcellulose and stirred 
for 20 minutes at room temperature. Another 150 ml of medium was then added and the 
solution stirred at 4 °C overnight. The solution was then split into 50 ml sterile centrifuge 
tubes in the laminar flow hood. The tubes were then centrifuged for 2 hours at 5000 x g 
in a fixed head centrifuge at 23 °C, followed by a 40-minute centrifugation at 23 °C in a 
swinging bucket centrifuge at 3130 x g. The supernatant was then collected, pooled in 
sterile Schott bottles and stored at 4 °C. This solution is here referred to as 
methylcellulose solution. 
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4.4.3. Formation of spheroids and placement into PEG-VS hydrogels 
 
HUVECs were cultured in enriched culture medium to between P2 and 4 and allowed to 
reach 75% confluency. The cells were then trypsinised, resuspended in standard culture 
medium and counted as detailed above. HUVECs were diluted to 5000 cells/ml with 6 ml 
methylcellulose solution and 24 ml standard culture medium. 150 µl of this cell 
suspension was added to each well of a round-bottom, 96-well plate (not tissue culture-
treated) to create spheroids of 750 cells. It is this viscous, methylcellulose-containing 
medium, as well as round, untreated wells that drives spheroid formation. The plate was 
incubated at 37 °C for 24 hours.  
 
PEG hydrogels were formed as per Table 2 or Table 3. Whilst the PEG-RGD mixture was 
incubated for 30 min at 37 °C, the spheroids created were assessed using a light 
microscope to ensure selection of the ones with the smoothest edges and those free of 
debris. The selected spheroids were harvested using a 1 ml pipette tip (cut so as to reduce 
sheer forces) and pooled into a 15 ml centrifuge tube. The tube was then centrifuged at 
244 x g for 3 minutes to pellet the spheroids. The supernatant was slowly removed and 
the pellet washed by addition of 200 µl TEOA, after which the previous centrifugation step 
was repeated. The spheroid pellet was then carefully aspirated along with 100 µl of the 
supernatant and added to a 0.6 ml centrifuge tube and centrifuged in a microfuge at 100 
x g for 3 minutes. Supernatant was removed from the tube (approximately the amount of 
TEOA one would need to make up to the final volume) and the pellet resuspended in the 
PEG-RGD mixture, followed by the MMP-1 peptide solution and heparin if desired. 
 
20 l hydrogels containing between 3 – 5 spheroids each were pipetted into the 
siliconised wells of a 24-well plate. Once the hydrogels had set for one hour, 1 ml of 
culture media, supplemented with VEGF (10 ng/ml), bFGF (10 ng/ml) or PlGF-2 (40 ng/ml 
and 100 ng/ml), was added. In the case of the negative control, only culture media was 
added. 
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Spheroids were incubated for 72 hours at 37 °C and 5% CO2, with micrographs captured 
using a phase contrast microscope (Nikon Eclipse Ti-S). Spheroids were incubated for 120 
hours in the case of the 8-arm hydrogels, and fluorescent staining carried out. 
 
4.4.4. Fixation, fluorescent staining and visualisation of 8-arm PEG-Ac/PEG-VS 
hybrid hydrogels 
 
After capturing micrographs at 120 hours, the media was removed and the hydrogels 
washed twice with PBS. The spheroids were then fixed using 10% formalin in PBS for 30 
minutes. The wash step was then repeated and the hydrogels permeabilised with 0.1% 
Triton-X in PBS for 4 minutes. The hydrogels were then washed 3 times and spheroids 
stained using ActinRed 555 Ready Probes reagent by adding one drop of the reagent to 5 
ml PBS. This solution was vortexed and 1 ml removed and added to 4 ml PBS. The 
hydrogels were then immersed in this diluted solution for 20 minutes at room 
temperature, after which they were washed 5 times with PBS. The spheroids were 
counterstained with Hoechst 33258 nuclear stain (1:4000 dilution) for 10 minutes at room 
temperature, followed by a PBS wash repeated 3 times. The hydrogels were then 
immersed in PBS and the plate was covered with tin foil until they were viewed using a 
ZEISS LSM510 Confocal microscope.  
 
For viewing, hydrogels were lifted out of the plate and placed onto glass coverslips to 
allow for viewing at a higher magnification than that possible when viewing the hydrogels 
in the 24-well plate. Z-stacked micrographs were obtained and ZEISS Efficient Navigation 
(ZEN, blue edition, 2012) image acquisition and processing software used to compress the 
Z-stacked micrographs. 
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4.4.5. Analysis of results 
 
The length of each sprout was determined using ImagesPlus software v2.0 (Motic, Hong 
Kong) – see  
Figure 25 below which shows the software interface.  
 
 
 
Figure 25: Measuring the length of each spheroid sprout 
using Motic ImagesPlus software. 
 
Once all the sprouts on the spheroid had been measured, cumulative sprout length was 
calculated by adding all the sprout lengths together. After all spheroids’ sprouts in that 
treatment group were measured, the cumulative sprout lengths were averaged to 
generate the average cumulative sprout length. Spheroids that were close together or 
touching, were excluded from the analysis, as well as spheroids too close to the hydrogel 
edge. All other spheroids were included in the analysis, regardless or sprout length or 
number. Sprout number per spheroid was also established. 
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4.5. Sustained release of growth factors from PEG hydrogels 
 
As 3.5% 4-arm PEG-VS gels were initially utilised in the spheroid sprouting assays, growth 
factor release from these hydrogels was assessed. 
 
4.5.1. 3.5% 4-arm PEG-VS hydrogels frow growth factor release 
 
To create cumulative release profiles, showing the release of each growth factor over a 
period of 20 days, 5 µl 3.5% PEG-VS (m/v) hydrogels were created.  
 
Petri dishes (35 x 10 mm) were lined with sterile Parafilm strips. The PEG hydrogels were 
created as in Table 1, with the hydrogel master mix volume adjusted accordingly. Each 
hydrogel contained 500 ng of growth factor, with the combination hydrogels containing 
500 ng of bFGF and 500 ng of PlGF-2. The growth factors were added to the master mix 
prior to the MMP-1 peptide, with their volume deducted from the TEOA volume seen in 
Table 1 so as not to alter the total mix volume. 
 
Four 5 µl gels per treatment were pipetted out onto the Parafilm and set at 37 C for 50 
minutes. Once set, the hydrogels were lifted off and placed into individual microfuge 
tubes containing 250 µl iso-osmotic PBS (with 1% BSA and 2% penicillin-streptomycin). 
The tubes were placed into a shaker (50 RPM, 37 C) for one hour (“Wash 1”) to remove 
unbound growth factor. This was repeated with the hydrogels placed into fresh iso-
osmotic PBS (“Wash 2”). 
 
The hydrogels were then again placed into fresh iso-osmotic PBS and only moved on the 
following days thereafter: Day 1, 2, 4, 6, 8, 12, 16 and 20. The eluent in each instance was 
frozen at -20 ° C after collection. 
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After the conclusion of the release assay on Day 20, the eluent samples (iso-PBS + eluted 
growth factors) were diluted accordingly and analyses were conducted by use of enzyme-
linked immunosorbent assays (ELISAs). 
 
4.5.2. ELISAs to quantify growth factor release 
 
DuoSet® ELISA Development System kits were obtained for human PlGF, VEGF and bFGF 
from R&D Systems (MN). Only PBS was used (pH 7.2 – 7.4) to dilute the capture antibody 
and reagent diluent (concentrated BSA, purchased from R&D Systems) solutions. All 
dilutions were carried out according to the manufacturer’s instructions and all 
incubations took place at room temperature. 
 
In brief, the capture antibodies were diluted to their respective working concentrations 
with PBS. 100 µl of this was then added to each well of an immunosorbent 96-well plate 
and incubated overnight. Note that during each incubation period the plate was covered 
with Parafilm to prevent evaporation and contamination. The wells were washed with 
400l wash buffer (0.05% Tween®20 in PBS) three times and then blocked with 300l 
reagent diluent (diluted accordingly) and incubated at 1 hour. The wash step was then 
repeated. 100 µl of each eluent sample, diluted (1:100) with reagent diluent, was added 
to the wells and incubated for 1 hour 30 minutes. 
 
The growth factor standards were prepared by serial dilution using fresh growth factor 
(that purchased from Peprotech, and used for the release assays, not that supplied in the 
kit). The standard curve was carried out in duplicate. After a 2-hour incubation period, 
the wash step was repeated and 100l of biotinylated detection antibody added to each 
well. After a 1 hour 30-minute incubation, the wells were washed once again and 100l 
of streptavidin-horse radish peroxidase (strep-HRP) was added to each well. 
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After the wells were incubated with strep-HRP at room temperature for 30 minutes, the 
wells were again washed and 100 l of the substrate solution (a 1:1 mixture of Solutions 
A and B – hydrogen peroxide and tetra-methyl-benzidine respectively – supplied in the 
colour reagent pack, R&D Biosystems) was added to each well. The plate was then 
incubated for 15 - 20 minutes and monitored for colourimetric changes. To stop the 
reaction, 50 µl of the stop solution (2 N H2SO4) was added to each well and the optical 
density read at 450 nm, with background correction at 570 nm, using an iMark microplate 
reader (BioRad, CA). 
 
The amount of growth factor released (ng/ml) on each selected day was calculated using 
the standard curve and used to create cumulative release curves. The amount of growth 
factor bound was calculated by subtracting the amount of growth factor contained in 
each wash from the total amount of growth factor loaded into each hydrogel. 
4.6. In vivo study: subcutaneous implant assay 
 
This study was approved by the Animal Research and Ethics Committee of the University 
of Cape Town (HSF AEC 014/016) and was in keeping with the Principles of Laboratory 
Care and followed the guidelines within the National Research Council’s Guide for the 
Care and Use of Laboratory Animals (National Institutes of Health, publication # 86-23). 
 
The 2 mm x 5.4 mm (thickness x diameter) polyurethane (P.U.) discs used were 
manufactured by the Polymer Laboratory as previously described by Bezuidenhout et al. 
(2002) [366]. The discs possessed an 82% porosity and pore sizes of 157 ± 1 µm. 
Sterilisation of the discs took place by immersion in a tube of 70% ethanol which was 
sonicated for 20 minutes. After placing the discs into the wells of a sterile 96-well plate, 
100 µl of the hydrogel solution (Table 3 and Table A5, Appendix 1) was pipetted onto the 
first disc. The disc was then repeatedly squeezed with a 1 ml syringe plunger to allow for 
air removal and hydrogel infiltration. 
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4.6.1. Subcutaneous implantation and subsequent removal of polyurethane discs 
 
The subcutaneous implants were carried out in male Wistar rats (n=4) as previously 
described by Goetsch et al. (2015) [120]. Note that aseptic technique was used for surgical 
procedures. 
 
 
Figure 26: Schematic depicting subcutaneous implant model in rats. P.U. discs were 
impregnated with the different hydrogels before polymerisation. Subcutaneous pockets 
were made along the dorsal midline (1) into which the discs were placed (2), with 6 
randomised discs per rat. The pockets were then sutured closed (3). Explants took place at 
2 and 4 weeks. Surgical images adapted from Pelhares et al. (2009). Scanning electron 
micrograph shows the porous nature of P.U. discs. 
 
After induction of anaesthesia using isoflourane, the animals were shaved and the surgical 
area prepared with povidine iodine. Longitudinal incisions, approximately 1 cm in length, 
were made on either side of the dorsal line (Figure 26). A pocket for each disc was then 
made, subcutaneously, by blunt dissection. The discs were then implanted into the 
pockets, with each rat obtaining one disc from each of the 5 groups. The incisions were 
then sutured closed using single 4.0 prolene sutures. It is to be noted that the individual 
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carrying out the surgery was blinded to the treatment groups and the implant position 
randomised for each animal. 
 
After 2 weeks had elapsed, half of the impregnated P.U. discs were excised, with the other 
half to be excised after 4 weeks. To do this, the animals were euthanised by halothane 
inhalation. The discs were then surgically excised post mortem.  
 
4.6.2. Histological processing and staining of implants 
 
The excised discs were cut in half with a scalpel so that the cross-sections could be stained 
and visualised. Each half was placed into a separate sample jar containing 10% buffered 
formalin for fixation. 24 hours later, the discs were placed into 70% ethanol before being 
processed. 
 
4.6.2.1. Wax processing and embedding 
 
The P.U. discs were removed from the ethanol and placed into histology cassettes. The 
cassettes were then placed into wire mesh baskets and immersed in graded alcohol (70% 
to 90%), for 60 minutes in each. The samples were then immersed in 100% alcohol three 
times for 60 minutes each. This was followed by 3 changes of iso-octane, and then 3 
changes of paraffin wax for 60 minutes each at 60 C, with the final change being 120 
minutes. 
 
The cassettes were then opened, the samples placed into embedding moulds and hot wax 
poured in. Once the blocks were turned out, the samples were sectioned using a 
microtome.  
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4.6.2.2. Staining 
 
Once mounted on microscope slides, sections were stained with haematoxylin and eosin 
(H&E) to quantify tissue invasion. First, the sections were dewaxed using 
trimethylpentane for 10 minutes. This was repeated twice more. The sections were then 
immersed in 100% alcohol three times, followed by two immersions in 96% alcohol and 
two in 70% alcohol. This was followed by immersion in distilled water. The slides were 
then placed in haematoxylin and then under running tap water, both for 5 minutes. The 
slides were then moved to eosin for 30 seconds, dipped into distilled water and then 
immersed in the alcohols mentioned above. Coverslips with a drop of Canada Balsam 
were then inverted and placed on top of the sections and allowed to dry.  
 
In order to visualise the presence of collagen fibres, a picrosirius red stain was used. The 
sections were dewaxed as aforementioned, followed by staining with Weigert’s 
haematoxylin for 8 minutes and a wash under tap water for 10 minutes. Picrosirius red 
staining was then conducted for 1 hour, and the sections wash twice in acidified water. 
Water was removed from the slides by shaking and the sections were dehydrated using 
three changes of 100% ethanol. Coverslips were then mounted onto the samples and 
allowed to dry. 
 
4.6.2.3. Microscopic viewing and analysis 
 
The H&E- and picrosirius red-stained sections were viewed at 100 x magnification using a 
Nikon 90i microscope and micrographs captured. These were then stitched together using 
the Nikon Eclipse software to form one image of the entire disc cross-section. Analysis 
was then conducted using Visiopharm Integrated Systems (VIS) analysis software by an 
individual that was blinded to the treatment groups. The amount of tissue ingrowth was 
quantified manually from the H&E-stained sections. Collagen fibre presence was then 
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quantified by training the VIS software to detect picrosirius red staining using the decision 
forest classifier machine learning model. 
 
4.7. Statistical analyses 
 
All statistical analyses were conducted using IBM SPSS Statistics v25.0.0 (IBM Corporation, 
NY), unless otherwise stated below, with statistical significance being defined as p<0.05 
(*) and P<0.01 (**). Errors bars are either represented as standard deviation (SD) or 
standard error of the mean (SEM). 
 
Once normal distributions were confirmed by Shapiro-Wilk testing, mean values between 
groups were compared using One-way Analysis of Variance (ANOVA) followed by the 
Tukey HSD post-hoc test for the spheroid assays. 
 
Analyses of all other data were conducted using Student’s T-tests [two-sample equal 
variance (homoscedastic)] in Excel (Microsoft Office for Mac version 15.32). 
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5. Appendices 
 
Appendix 1: Recipes and reagents 
 
All of the constituents for the solutions below were first dissolved in a beaker containing 
800 ml Nanopure water. The pH was then corrected to pH 7.4 using NaOH/HCl and the 
solution brought up to the final volume of 1 L in a volumetric flask, unless otherwise 
specified. If needed, the solutions were then sterilised by autoclaving. For cell culture 
media, sterilisation was carried out using a vacuum pump attached to a 0.22 µm low 
protein-binding Schott bottle filter and stored at 4 °C. 
 
Table A1: MCDB 131 culture medium recipe and constituents (for 1L) 
Constituents Amount added 
MCDB 131 (powdered) 1 bottle (11.6 g) 
Sodium bicarbonate 1.18 g 
Nanopure H2O 1 L 
 
Table A2: DMEM culture medium recipe and constituents (for 1 L) 
Constituents Amount added 
DMEM (powdered) 1 bottle (13.4 g) 
Sodium bicarbonate 3.7 g 
Nanopure H2O 1 L 
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Table A3: Phosphate-buffered saline (PBS) recipe and constituents (for 1 L) 
Constituents Amount added 
NaCl (137 mM) 8 g 
KCl (2.7 mM) 0.2 g 
KH2PO4 (1.4 mM)  0.2 g 
Na2HPO4.12H2O (8 mM) 2.9 g 
Nanopure H2O 1 L 
 
Table A4: Iso-osmotic PBS recipe and constituents (for 1L) 
 Constituents Amount added 
Solution A NaH2PO4.H2O 20.7 g 
Solution B NaH2PO4.12H2O 53.7 g 
Solution C NaCl 9 g 
 
Iso-osmotic PBS 
 
65 ml Solution A + 435 Solution B + 500ml Solution C 
*Note that pH was correct to pH 7.4 using Solution A and B, not NaOH or HCl 
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Table A5: 8-arm PEG-VS hydrogels for subcutaneous implants – to make a 100 µl 
hydrogel 
Gel constituents Volume (µl) 
8-arm PEG 
PEG-VS 
PEG-Ac 
 
PEG-VS 
PEG-Ac 
 
 
PEG-VS 
PEG-Ac 
 
 
PEG-VS 
PEG-Ac 
For 0% PEG-Ac hydrogels: 
40*                                 40 µl total 
0* 
For 25% PEG-Ac hydrogels: 
30*                                   40 µl total 
10* 
 
For 75% PEG-Ac hydrogels: 
10*                                   40 µl total 
30* 
 
For 100% PEG-Ac hydrogels: 
0*                                    40 µl total 
40* 
MMP-1 33** 
Heparin 4 (of a 1.5% solution in iso-PBS) 
RGD 9.84 
Iso-PBS 13.16 
TOTAL 100 
* of a 10% stock solution in iso-PBS 
** of a solution made by addition of 9 mg MMP-1 recognition peptide to 214.2 µl iso-PBS 
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Many experiments to follow involved the use of growth factors, all of which were 
obtained from Peprotech, Rocky Hill, NJ. Before growth factors could be utilised in these 
experiments, they were reconstituted using diluents specified by the manufacturer (Table 
A6) to a stock concentration of 1 g/l and stored at -20 C. 
 
Table A6: Solutions for reconstitution of growth factors 
Growth factor Diluent 
   bFGF    5 mM Tris, pH 7.6 
   EGF     
   Sterile, de-ionised H2O 
    
   PlGF-2 
   VEGF 
 
When diluting growth factors to concentrations needed experiments, sterile 0.1% BSA-
PBS was used. The carrier protein (BSA) was included to prevent binding of the growth 
factors to the storage tubes. 
 
Table A7: Collagenase recipe and constituents 
Constituents Amount added 
Collagen type II powder 168 g 
Nanopure H2O 240 ml 
 
Once the collagen powder was weighed, it was added to the PBS and was stirred in a 
beaker (covered with tinfoil to prevent exposure to light) until dissolved. The solution was 
then filtered and aliquoted into 50 ml tubes. The tubes were covered in tinfoil and frozen 
at -20 °C. When ready to use, the tubes were slowly thawed at room temperature. 
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Table A8: Triethanolamine (TEOA) recipe (0.3 M) 
Constituents Amount added 
TEOA  2.24 g* 
Nanopure H2O 50 ml 
*Note the TEOA was weighed rather than volumetrically measured due to its viscosity. 
 
After the 2.24 g of TEOA was weighed, 30 ml of Nanopure H2O was added. The solution 
was vortexed and then corrected to pH 7.4 (with NaOH or HCl) and made up to a final 
volume of 50 ml using a volumetric flask. The solution was then sterilised using a syringe 
filter. 
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Appendix 2: Details of all specialised reagents used 
 
Table A9: Growth Factors 
Product Producer / Supplier Product Catalogue Number 
Human fibroblast growth 
factor-basic (bFGF) 154 a.a. 
Peprotech, Rocky Hill, NJ 100-18B-100UG 
Human epidermal growth 
factor (EGF) 
AF-100-15 250µg 
Recombinant human 
placental growth factor-2 
(PlGF-2) 
100-56-100UG 
Recombinant Human 
vascular endothelial 
growth factor 165 (VEGF) 
100-20-10UG 
 
  
 121 
Table A10: ELISA kits, ancillary products and consumables 
 Product Manufacturer Product Catalogue 
Number 
ELISA kits DuoSet® ELISA 
Development system – 
Human bFGF 
R&D Systems, 
Minneapolis, 
MN 
DY233 and DY233-
05 
DuoSet® ELISA 
Development system – 
Human PlGF 
DY-264 
DuoSet® ELISA 
Development system – 
Human VEGF 
DY293B-05 
 
Ancillary products Reagent diluent 
concentrate 1 
DY997 – 21ml 
Consumables Maxisorp 96-well plates, 
non-sterile 
Nunc, Roskilde, 
Denmark 
44-2404-21 
 
Table A11: PEG hydrogel constituents 
Product Manufacturer Product Catalogue Number 
PEG-OH 20 kDa, 4-arm Nektar Therapeutics, 
Huntsville, AL  
 
0J000P04  
PEG-OH 20 kDa, 8-arm 0J000P08 
PEG-Ac 20 kDA, 8-arm Jenkem, Plano, TX no catalogue number 
RGD (GCGYGRGDSPG, MW = 
1025.06g/mol) 
GenicBio Synthetic Peptide, 
Shanghai, China 
100 mg, no catalogue 
number on tube 
MMP-1 
(GCREGPQGIWGQERCG, 
MW = 1732.91g/mol) 
GenScript USA Inc., 
Piscataway, NJ 
U5878BB230-1 (100 mg per 
vile) 
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Appendix 3: Details of all general reagents used 
 
Table A12: Details of general reagents used 
Product Producer / Supplier Product Catalogue 
Number 
Actin RedTM ReadyProbes® 
Reagent 
Life Technologies R37112 
Alexa Fluor® 488 goat anti-
mouse IgG secondary 
antibody 
Molecular Probes®, (Life 
Technologies, USA) 
A11029 
Bovine serum albumin (IgG-
free, Protease-free) 
Jackson ImmunoResearch, 
Westgrove, PA 
001-000-162 – 50g 
Collagen type I (bovine skin) Sigma-Aldrich®, St Louis, 
MO 
C4243-20ML 
Collagenase type II (HUVEC 
isolation) 
Worthington Biochemical 
Corporation, Lakewood, NJ 
LS004174 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich®, St Louis, 
MO 
D2650 – 5X1ML 
DMEM D5648-10X1L 
Ethanol Servochem (PTY) LTD, 
Montague Gardens, Cape 
Town, RSA 
no catalogue number 
Fluoroshield with DAPI Sigma-Aldrich®, St Louis, 
MO 
F6057 – 20ml 
Foetal Bovine Serum (FBS) 
(gamma irradiated) – 1 
Gibco® by Life 
Technologies™, Paisley, UK 
10499-044 – 500ml 
Foetal Bovine Serum (FBS) 
Superior (heat inactivated) 
– 2 
 
Biochrom GmbH, Berlin, 
Germany 
S0615 – 500ml 
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Gentamicin solution Sigma-Aldrich, St Louis, 
MO 
G1272 – 10ml 
Hydrocortisone H0396-100MG 
L-Glutamine G-8540-100G 
Medium 199 growth 
medium (liquid) 
M4530 
 
Mouse anti-human CD31 
primary antibody 
(monoclonal) 
Dako, Agilent 
Technologies, C.A. 
M0823 
MCDB-131 Medium Sigma-Aldrich, St Louis, 
MO 
 
M8537 
Methylcellulose – 4000 
centipoises 
M-0512 100g 
Heparin NaCl H3393-50KU 
Heparin sodium, mucosal 
(5000 I.U./ml) 
Fresenius Kabi 
Manufacturing, 
Johannesberg, R.S.A 
no catalogue number 
Hoechst 33258 ThermoFischer Scientific, 
OR 
H3569 – 10 ml 
Hydrochloric acid (HCl), 25% 
w/v 
Honeywell Riedel-deHaën, 
Seelze, Germany 
30723 – 2.5L 
Penicillin Streptomycin 
(10 000 U penicillin and 
10 mg streptomycin/ml)  
Sigma-Aldrich®, St Louis, 
MO 
P0781 (100X 
concentration) 
Penicillin Streptomycin 
(10 000 U/ml / 10 000 
µg/ml) 
 
Gibco® by Life 
Technologies, Carlsbad, CA 
15140-122 (100 ml) 
Sigmacote® Sigma-Aldrich®, St Louis, 
MO 
SL2-100mL 
Sodium bicarbonate 
(NaHCO3)  
S-5761-1KG 
 124 
Sodium Chloride (NaCl) S-7653-1KG 
Sodium Dodecyl Sulfate – 
SDS 
L3771-100G 
Sodium Hydroxide (NaOH) S-5881-500G 
Sodium Phosphate Dibasic 
Dodecahydrate 
(Na2HPO4.12H2O) 
71649-500G 
Sodium Phosphate 
Monobasic Monohydrate 
(NaH2PO4.H2O) 
S9638-500G 
Triethanolamine (TEOA) 
99% 
Saarchem-Holpro Analytic, 
Krugersdorp, R.S.A 
6112040 -2.5L 
Triton-X (used to 
permeabilise PEG) 
Sigma Aldrich®, St Louis, 
MO 
 
T8532 – 500ML 
Trypan Blue T8154-100ML 
Trypsin-EDTA (10X) 100ml 59427C-100ML 
Tween® 20 P1379 
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Appendix 4: Details of all consumables used 
 
Table A13: Details of general consumables used 
Product Producer / Supplier Product Catalogue 
Number 
40 µl Cuvette Pack of 100 
with stoppers 
Malvern Instruments LTD., 
Worcestershire, UK 
ZEN0040 
0.6ml Graduated 
Microcentrifuge Tube with 
flat cap 
Thermo Scientific QSP, San 
Diego, CA  
 
502-GRD-Q 
1.5ml Graduated 
Microcentrifuge Tube with 
flat cap 
509-GRD-Q 
2ml Graduated 
Microcentrifuge Tube with 
locking cap 
L-508GRD-Q 
24-well clear, flat 
bottomed, sterile tissue 
culture treated plate   
Corning Inc., Corning, NY Costar® 3524 
96-well clear, flat 
bottomed, sterile tissue 
culture treated plate   
3595 
96-well clear, round 
bottomed, sterile plate, 
non-tissue culture treated 
Thermo Scientific™ Nunc™, 
Roskilde, Denmark 
268200 
15ml centrifuge tube Falcon by BD Biosciences, 
San Jose, CA 
352096 
50ml centrifuge tube Thermo Scientific™ 
Nalgene™, Waltham, MA 
352070 
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Mr Frosty freezing 
container, Nalgene  
Sigma-Aldrich®, St Louis, 
MO 
C1562 
Parafilm M® 4 in. X 250 ft. 
roll 
Bemis NA, Neenah, WI PM 999 
Straight-side Wide-Mouth 
Jar (1 L)– for umbilical cord 
incubation 
Thermo Scientific™ 
Nalgene™, Waltham, MA 
2116-1000 
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Appendix 5: Details of all equipment used 
 
Table A14: Details of equipment used 
Product Producer / Supplier 
Centrifuge – J2-21 with a 
JA20 rotor, for centrifuging 
methylcellulose 
Beckman Coulter Life Sciences, Indianapolis, IN 
Centrifuge – Megafuge 1.0R Heraeus, Hanau, Germany 
Centrifuge – 5415R (for 
microcentrifuge tubes) 
Eppendorf, Hamburg, Germany 
Freeze Dryer – VirTis SP Industries, Gardiner, NY 
Haemocytometer Improved Neubauer, Baxter Scientific, Deerfield, IL 
iMark plate reader Biorad, Hercules, CA 
Incubator (for all 37 °C cell 
culture) 
HERA Cell by Heraeus, Hanau, Germany 
MCO-175M, O2/CO2 
Incubator 
Osaka Sanyo Electric Co., Osaka, Japan 
Microscope – Nikon Eclipse 
Ti-S Light microscope 
 
Nikon, Tokyo, Japan 
Microscope – Nikon 
Fluorescent Microscope 
(Nikon Eclipse 90i DS-Ri1) 
Microscope - ZEISS LSM510 
Confocal microscope with 
MaiTai two photon laser 
Carl Zeiss Microscopy GmbH, Göttingen, Germany 
pH meter – 3510 Jenway by Bibby Scientific, Staffordshire, UK 
Pipettes Gilson, Inc. Middleton, WI 
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Rheometer - Kinexus Pro Malvern Instruments, UK 
Shaking incubator IncoShake by Labotech, Cape Town, RSA 
Water Bath – Grant Y14 Grant Instruments, Cambridge, UK 
37°C incubator for tissue 
culture 
MCO-175M, O2/CO2 Incubator, Osaka Sanyo Electric 
Co., Japan 
Heraeus, Hanau, Germany 
-65 °C freezer Snijders Scientific, Tilburg, Netherlands 
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